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i. Abstract  
 
Hypertension is one of the most common medical conditions complicating pregnancy, 
with significant implications on maternal and perinatal morbidity and mortality.  
Abnormalities in placentation have been implicated as the primary pathology 
responsible for the development of hypertension during pregnancy and its effects such 
as pre-eclampsia and eclampsia. With advancing research, the focus is now gradually 
shifting towards abnormalities in the maternal vasculature, including endothelial 
damage/dysfunction and impaired repair as a probable cause for this, with the latter 
also being implicated in the development of cardiovascular disorders in later life in 
these women. 
 
Hypertensive disorders occur in 6-8% of pregnancies. They also determine and 
influence the development of cardiovascular disease (CVD) in the mother in later life. 
Hypertension, obesity, metabolic syndrome and CVD are commoner in women with 
pre-eclampsia and preterm deliveries, whereas the risk of cerebrovascular disease is 
much higher in those with recurrent spontaneous abortions. 
 
This research thesis is a study of the various processes occurring in the maternal 
vasculature, including angiogenesis, apoptosis, endothelial damage and 
regeneration/repair, the extra-cellular matrix and the haem oxygenase systems, the 
abnormalities that occur in them and their associations with hypertensive disorders of 
pregnancy and their complications. 
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1.1. Hypertension in pregnancy: an overview 
Hypertension is the most common medical condition that occurs in pregnancy, and a 
leading cause of maternal mortality, as well as other serious effects on pregnancy 
outcomes. (1) 
The following chapter is a synopsis of hypertension in pregnancy and its evaluation 
and management. 
Classification of Hypertension in Pregnancy 
Hypertensive disorders are classified into 4 categories according to the Working 
Group Report on Hypertension in Pregnancy as chronic hypertension, preeclampsia-
eclampsia, preeclampsia superimposed upon chronic hypertension and gestational 
hypertension (Table 1.1.1).(1) 
Chronic hypertension is hypertension (blood pressure ≥140 mm Hg systolic and/ or 
≥90 mm Hg diastolic) that is present and observable before pregnancy or diagnosed 
before the 20th week of gestation as well as that diagnosed for the first time during 
pregnancy and persistent postpartum. 
Preeclampsia-eclampsia is a pregnancy-specific syndrome that usually occurs after 20 
weeks’ gestation, or earlier in trophoblastic diseases (hydatidiform mole or hydrops). 
The increased blood pressure is accompanied by proteinuria in this syndrome. 
Preeclampsia is a syndrome characterized by hypertension, proteinuria and symptoms 
of headache, visual changes, epigastric or right upper quadrant pain and dyspnea. 
Several factors have been identified to be associated with an increased risk of 
preeclampsia such as age, parity, previous preeclampsia, family history, multiple 
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pregnancy, pre-existing medical conditions (insulin dependent diabetes mellitus 
(IDDM), obesity and insulin resistance, chronic hypertension, renal disease, auto-
immune disease, anti-phospholipid syndrome, rheumatic disease), smoking, increased 
body mass index (BMI), raised blood pressure and proteinuria. In addition, couple-
related factors including limited sperm exposure, primipaternity, pregnancies after 
donor insemination/ oocyte/ embryo donation have been found to play an important 
role too. 
Eclampsia is the occurrence of seizures in a woman with preeclampsia that cannot be 
attributed to other causes.  
Gestational hypertension or pregnancy induced hypertension (PIH) occurs with a 
blood pressure >140/90 mm Hg in a woman who was normotensive before 20 weeks’ 
gestation. Severe gestational hypertension is a condition of sustained elevation in 
blood pressure of >160/110 mm Hg for 6 hours. Blood pressure normalizes in the 
postpartum period usually within 10 days. Patients may experience headache, blurred 
vision, abdominal pain and are noted to have abnormal lab tests, including low 
platelet counts and abnormal liver function tests.  
Preeclampsia may occur in women with chronic hypertension, with a much worse 
prognosis than with either condition alone. (2) Superimposed preeclampsia is difficult 
to distinguish from worsening chronic hypertension, with possible findings that 
include new onset proteinuria in women with hypertension and no proteinuria in early 
pregnancy (<20 weeks’ gestation), sudden increase in proteinuria or blood pressure in 
a woman with previously well controlled hypertension, thrombocytopenia (<100,000 
platelets/mm3) or abnormal elevation in liver enzymes (alanine aminotransferase or 
aspartate aminotransferase). (2) 
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Measurement of blood pressure 
Measurement of diastolic blood pressure during pregnancy has been a topic of debate. 
The National High Blood Pressure Education Program Working Group on High 
Blood Pressure in Pregnancy (NHBPEP) recommends the use of Korotkoff phase V. 
Pathophysiology 
Preeclampsia is caused by the presence of the placenta or the maternal response to 
placentation. Poor placentation is a strong predisposing factor that leads to the 
maternal syndrome, the extent of which is related to the inflammatory signals 
(dependent on foetal genes) as well as the nature of the maternal responses (dependent 
on maternal genes). 
Two diverse theories, vascular (ischemia-reperfusion resulting in oxidative stress and 
vascular disease) and immune (maternal-paternal immune maladaptation, i.e. a 
maternal alloimmune reaction triggered by a rejection of foetal allograft) are 
hypothesized to be responsible for preeclampsia. The aetio-pathophysiology of 
preeclampsia is complex and involves diverse factors such as genetic predisposition, 
disturbances in the renin-angiotensin-aldosterone axis, dysfunction of the maternal 
endothelium, maternal coagulopathies, cytokines, growth factors etc. (3, 4) 
Is preeclampsia predictable? 
Though various clinical and laboratory tests [Table 1.1.2] are currently used to predict 
the risk of women developing preeclampsia, no test reliably predicts preeclampsia. 
The importance of clinical history cannot be over-emphasized here. 
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Prevention of preeclampsia 
Several measures such as calcium supplementation, low dose aspirin, fish oils, etc. 
have been suggested to help prevent preeclampsia with varied results. 
Management of hypertension in pregnancy 
Baseline laboratory investigations (haematocrit, haemoglobin concentration, and 
platelet count and serum creatinine and uric acid levels) early during gestation, with 
monitoring of levels are particularly useful in the early diagnosis of preeclampsia. 
Proteinuria of 1+ by routine urinalysis is an indication for a 24-hour collection for 
protein and creatinine estimation, to determine accuracy of collection and estimation 
of creatinine clearance. Accurate dating (with ultrasonographic methods, if required) 
and assessment of foetal growth in high-risk patients is important, as is a baseline 
sonogram at 25 to 28 weeks’ gestation to evaluate foetal growth.  
In women presenting with hypertension after mid-pregnancy, laboratory tests are 
recommended, with biweekly monitoring to distinguish preeclampsia from chronic 
and transient hypertension as well as to assess disease progression and severity. One 
or more abnormalities may be present in women with preeclampsia despite relatively 
minimal blood pressure elevations. A life threatening abnormality such as 
coagulopathy or abnormal hepatic and/or renal function may necessitate termination 
of pregnancy despite only mild hypertension.  
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Chronic hypertension in pregnancy 
Women with hypertension require a full assessment of the severity of hypertension 
and advice on lifestyle changes (restriction of daily activities, refraining from 
vigorous exercise, restriction of daily sodium intake, stopping smoking and alcohol 
intake). Discontinuation of drugs known to be harmful to the foetus is particularly 
important, with a switch to safer alternatives. Those with target organ damage should 
be warned regarding the higher risk for adverse neonatal outcomes particularly in 
cases with early onset proteinuria.  
Treatment of chronic hypertension 
Careful evaluation and monitoring of blood pressures is all that may be required in 
most patients, particularly in the context of a physiological drop in blood pressure 
during the first half of pregnancy.  
However, treatment may need to be continued in those with long-standing 
hypertension and target organ damage.   
Management of preeclampsia 
Delivery of the baby is the definitive treatment. However, the decision to deliver 
would need to take into account both maternal as well as foetal well-being and would 
depend on foetal gestational age, foetal status and severity of the maternal condition at 
assessment. 
Some indications for delivery include severe overt clinical symptoms in the mother, 
grossly abnormal lab tests and foetal ill-health. (5) 
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Pharmacologic treatment  
Antihypertensive treatment essentially prevent potential cerebrovascular and 
cardiovascular complications, the most common cause of maternal morbidity and 
mortality and do not prevent or alter the natural course of the disease in women with 
mild preeclampsia. 
The commonly used drugs in the treatment of hypertension in pregnancy are 
methyldopa, labetalol, nifedipine. Magnesium sulphate is used in the management of 
preeclamptic patients to prevent eclamptic seizures. Sodium nitroprusside is the drug 
of choice in hypertensive crisis. Nitroglycerine is a mixed arterio-venous dilator and 
the drug of choice in preeclampsia associated with pulmonary oedema and control of 
hypertension associated with tracheal manipulation, though it is contraindicated in 
hypertensive encephalopathy due to its effects on cerebral perfusion and intracranial 
pressure. Recent guidelines issued by the National Institute of Health and Clinical 
Excellence (NICE) are comprehensive and stress the importance of a multi-
disciplinary approach in the management of hypertensive disorders during 
pregnancy.(6) 
Hypertensive Emergencies 
Hypertensive encephalopathy, acute left ventricular failure, acute aortic dissection or 
increased circulating catecholamines (phaeochromocytoma, clonidine withdrawal) are 
acute emergencies that require urgent blood pressure lowering due to their potentially 
life-threatening consequences, particularly in women with underlying heart disease, 
chronic renal disease, multiple drug therapy to control hypertension, superimposed 
  
15 
 
preeclampsia in the second trimester and abruptio placentae with disseminated 
intravascular coagulation (DIC). (7) 
Conclusions 
Hypertension in pregnancy is an important medical condition with profound effects 
on the health of the mother and the foetus, the care of which requires a multi-
disciplinary approach towards a safe and uneventful pregnancy and delivery. 
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TABLE 1.1.1 HYPERTENSIVE DISORDERS OF PREGNANCY 
 
 
FINDINGS 
 
 
CHRONIC 
HYPERTENSION 
 
 
GESTATIONAL 
HYPERTENSION 
 
PREECLAMPSIA- 
ECLAMPSIA 
Time of onset of 
hypertension 
< 20 weeks of 
gestation 
After mid 
pregnancy 
≥ 20 weeks of 
gestation 
Proteinuria Absent Absent Present 
Haemo- 
concentration 
Absent Absent Present 
Thrombocytopenia Absent Absent Present 
Hepatic 
dysfunction 
Absent Absent Present 
Serum creatinine 
> 1.2mg/dL 
Absent Absent Present 
Raised serum uric 
acid  
Absent Absent Present 
Clinical 
Symptoms 
Absent Absent Present 
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TABLE 1.1.2. TESTS FOR PREECLAMPSIA 
 
 
Clinical Tests 
Average second trimester Mean Arterial Pressure (MAP) ≥ 90 mm Hg 
Angiotensin infusion test 
Roll-over test 
Uterine artery Doppler waveforms 
 
Laboratory tests 
Urinary calcium 
Urine kallikrein to creatinine ratio 
Plasma fibronectin 
Serum inhibin 
Serum Alpha feto protein (AFP)/ hCG (human chorionic gonadotrophin) 
Serum urate 
Haematocrit 
Antithrombin III 
Plasminogen activator inhibitors (1 and 2) 
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1.2. Endothelial dysfunction and hypertension in pregnancy 
 
Endothelial integrity and function has been described to be paramount to maintenance 
of vascular haemostasis and blood pressure control. (8) Furthermore, it has been 
suggested that either endothelial dysfunction is present before pregnancy and 
predisposes women to hypertension in pregnancy and pre-eclampsia, or that the latter 
induces long-term changes in endothelial function, which could have implications for 
development of cardiovascular disease in later life. (9) Circulating endothelial cells 
(CECs), a novel means of assessing endothelial dysfunction, are mature cells detached 
from the vascular intimal layer in response to a variety of insults. Endothelial 
progenitor cells (EPCs) are non-leukocyte cells derived from the bone marrow with 
proliferative potential that may be important in vascular regeneration. 
This chapter aims to provide an overview of current literature and concepts relating 
endothelial damage/dysfunction and impaired repair and the hypertensive disorders in 
pregnancy, with particular focus on CECs and EPCs. 
Circulating Endothelial Cells (CECs)  
Endothelial cells, as the name suggests, form the inner lining of the vascular tree and 
adhere to the basement, with little cell loss and subsequent clearance by the reticulo-
endothelial system in healthy individuals. Complex pathological mechanisms such as 
mechanical injury, atherosclerotic processes, abnormalities in endothelial cellular 
adhesion molecules, matrix proteins and various apoptotic processes cause damage to 
the endothelial lining resulting in endothelial cell detachment, hence increasing CEC 
numbers in the blood stream. (10-12) 
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CECs are defined phenotypically by the expression of endothelial markers (e.g. von 
Willebrand factor, VE-cadherin, CD146) together with the absence of the expression 
of leukocyte (CD45) and immaturity markers (CD133). Amongst these, CD146 has 
evolved as the most popular marker for their identification, being concentrated at the 
endothelial junction where it plays a key role in the control of cell-cell cohesion, 
permeability and signalization. (13-18) 
Isolation and quantification of CECs 
The precise quantification of CECs has been difficult in view of their low numbers in 
circulation as well as differing morphological appearances (Figure 1.2.1). However, 
developments in cell enrichment and labelling techniques have improved their 
detection. CECs are counted in whole blood using either immunomagnetic separation 
technique (with CD146-coated immunomagnetic beads) and cellular counter staining 
using fluoroscein isothiocyanate-stained endothelial specific Ulex Europeus lectin or 
using flow cytometry. (19) 
The immunobead method involves the use of 4.5 micrometre ferrous beads bound to 
an anti-CD146 monoclonal antibody.  These coated beads are mixed with venous 
blood in a head over head mixer for 30 minutes at 4oC. The anti-CD146 coated beads 
and blood/buffer mixture are placed in front of a magnet. The anti-CD146 coated 
beads (typically 5 x 107/ml of blood) bind to the CD146 epitope on the CECs and the 
magnet is then used to separate the bead-coated CECs from the other blood 
constituents. The unbound cells are washed away with buffer, and the bound cells are 
retained on the magnet. Following additional wash cycles, the cells are re-suspended 
in buffer and labelled (e.g. with acridine orange) before manual counting in a glass 
counting chamber under a fluorescent microscope. The use of an Fc blocking agent 
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(to prevent non-specific leukocyte binding) and relatively endothelial specific Ulex 
Europeus lectin 1 has improved the specificity of this technique. The endothelial (and 
non-leukocyte) origin of CD146-defined CECs has been amply demonstrated by co-
marking with, for example, vWf, endothelial nitric oxide synthase and E-selectin. (19)  
Subsequently, CECs are defined, on fluorescent microscopy, as cells 10 to 50 µm in 
size with four or more immunobeads attached and staining positive for fluoroscein 
isothiocyanate-stained Ulex Europeus (Figures 1.2.2 & 1.2.3a). 
CECs can also be isolated using flow cytometry, where whole blood is labelled with 
monoclonal antibodies tagged with fluorochromes; of note, this is also used to isolate 
EPCs and is discussed in detail later in this paper. Although this technique permits 
rapid multi-parametric analysis and the ability to detect sub-populations, there is 
potential for error in measurement as a result of inadequate standardization of flow 
conditions. For instance, the gating of the forward and side scatter as well as the 
threshold may collect measurements not only for intact CECs but also aggregates of 
leukocyte-endothelial cells as well as endothelial cell micro particles. The 
fluorescence measurements will be difficult to interpret since a consequence of the 
choice of gating is that measurements include many non-CECs. (10) 
Although the immunobead method is a very specific method of CEC identification 
(with values in the order of 10 cells/ml), flow cytometry is more sensitive, often 
reporting greater numbers, up to 1000-fold higher than the former method.  
CECs, endothelial damage/dysfunction and disease 
Endothelial damage/dysfunction has been shown to be associated with a wide range of 
cardiovascular disease manifestations including hypertension, diabetes mellitus, atrial 
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fibrillation, heart failure, peripheral vascular disease, coronary artery disease and 
cerebrovascular disease. (19-38) Endothelial damage/dysfunction is measured using a 
variety of markers such as von Willebrand factor (vWf), soluble E-selectin, soluble 
thrombomodulin, [sTM]), reduced flow mediated dilatation (FMD) and impaired skin 
blood flow response using laser Doppler flowmetry. 
Evidence to support an association between CECs and endothelial dysfunction has 
been mounting. An inverse correlation between CECs and FMD, a surrogate 
physiological marker of a perturbed endothelium has been previously demonstrated, 
(34, 35) as also a strong correlation between CECs and several plasma markers of 
endothelial damage (vWf, tissue plasminogen activator, soluble E-selectin). (34-38)  
CECs are rarely found in healthy individuals, with typical counts being <3 cells/ml. 
Elevated numbers of CEC have been identified in a wide range of disease states, 
including those with underlying auto-immune, neoplastic, infective, haematological 
and thrombotic aetiologies.  Further, longitudinal quantification of CECs in different 
diseases has shown variable levels according to the clinical condition/severity, 
suggesting its usefulness to monitor stable state, disease flare ups and response to 
treatment. (19) 
CECs, endothelial damage/dysfunction and hypertensive disorders in pregnancy 
Endothelial dysfunction has been described to play an important role in the 
pathogenesis of preeclampsia. Dysfunctional endothelial cells produce altered 
quantities of vasoactive mediators, which lead to a tip in the balance towards 
vasoconstriction. An imbalance in circulating angiogenic factors is emerging as a 
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prominent mechanism that mediates the endothelial dysfunction and the clinical signs 
and symptoms of preeclampsia. (39) 
Data on CECs in hypertensive disorders of pregnancy are limited. (Table 1.2.1)  For 
example, Canbakan et al (40) reported an increase in the number of circulating 
endothelial cells in women with preeclampsia (n=20) compared with healthy pregnant 
women, hypertensive women and non-pregnant controls (n=15 each). Preeclamptic 
patients had elevated numbers of CECs (13.2±5.2 cells/ml) compared with 
hypertensive patients (6.9±0.8 cells/ml), healthy pregnant women (5.2±1.4 cells/ml) 
and non-pregnant controls (4.0±1.8 cells/ml), (P<0.0001).  
There is further evidence of an association between other indices of endothelial 
damage/dysfunction and hypertensive disorders in pregnancy, with other markers 
such as von Willebrand Factor (vWF), thrombomodulin and E-selectin, which are also 
noted to be raised in hypertension in pregnancy. (41) 
Endothelial Progenitor Cells (EPCs) 
Endothelial Progenitor Cells are a heterologous population of largely bone marrow-
derived large non-leucocyte cells with properties similar to embryonal angioblasts, at 
different stages of maturation, from early (vascular endothelial growth factor receptor 
[VEGFR]/CD133+) to a more mature (VEGFR/CD34+) phenotype. EPCs are viable, 
can form colonies in vitro, have the capacity to differentiate into mature endothelial 
cells, and line the internal elastic membrane of the blood vessel. Hence, EPCs 
represent a subset of cells at varying stages of development present in the peripheral 
blood stream. (17, 18, 42-44) 
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However, more recent studies have challenged the above theories and have examined 
the origin as well as function of endothelial progenitor cells, although in the context 
of atherosclerosis and in animal models. (45, 46) 
Bentzon et al (45) studied the origin of plaque smooth muscle cells in apoE-/- mice by 
a series of bone marrow transplantations and in models of atherosclerosis induced by 
surgically transferred arterial segments. Their experiments confirmed that smooth 
muscle cells in atherosclerotic plaques are exclusively derived from local vessel wall. 
(45) 
In a subsequent study, Hagensen et al (46) investigated whether endothelial progenitor 
cells in the circulating blood  are a source of plaque endothelial cells during 
atherogenesis. Their experiments also looked at plaques in lethally irradiated apoE-/- 
mice reconstituted with bone marrow cells from enhanced green fluorescent protein 
(eGFP) transgenic apoE-/- mice and plaques induced in segments of common carotid 
artery transplanted from apoE-/- mice into eGFP+ apoE-/- mice. The findings of their 
study also suggested that circulating endothelial progenitor cells rarely contribute to 
plaque endothelium. (46)Isolation and quantification of EPCs 
EPCs can be isolated and quantified using Flow Cytometry. Red blood cells from a 
fresh sample of K3 EDTA anti-coagulated blood are lysed with BD lysing solution. 
The sample is gently inverted continually for 10 minutes following by centrifugation 
at 700G for 5 minutes. The obtained pellet is washed with a buffer solution 
[phosphate buffered saline (PBS), 5% bovine serum albumin BSA)] and then 
centrifuged again and washed twice. The resulting pellet is re-suspended and blocked 
with the Fc-receptor blocking antibody Octagam and 10% mouse blocking serum 
followed by incubation with CD133-PE (PhycoErythrin), CD45-FITC (Fluorescein 
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IsoThioCyanate) and CD34-PECy5 (PhycoErythrin Cy5) fluorochrome-labelled 
monoclonal antibodies for 20 minutes in the dark at 4ºC. The sample is then washed 
and centrifuged. The resulting cell pellet is re-suspended and fixed in 2% 
paraformaldehyde solution, before making it up to a 1mL sample with PBS-BSA 
buffer solution, ready for immediate flow cytometric analysis. Analysis is performed 
using a flow cytometer. CPCs are enumerated as a count of CD34+, CD133+, CD45- 
events per 1,000,000 collected events (Figure 1.2.3b). 
Another method for the characterisation and quantification of EPCs is based on the 
culture of endothelial cells from circulating mononuclear cells. (47) This involves the 
isolation of peripheral blood mononuclear cells by density centrifugation of blood and 
subsequent culture on fibronectin coated plates. After 5–7 days in culture, adherent 
colonies are seen, where spindle shaped cells emerge from a cluster of round cells 
(EPC colony forming units, EPC-CFUs). These adherent cells display a variety of 
endothelial-like properties including the uptake of acetylated low density lipoprotein 
(AcLDL) and staining with UEA-1, a lectin of Ulex Europeus, specific for endothelial 
cells in a variety of tissues binding to the carbohydrate moiety al-fucose. (48) Whilst 
counting EPC-CFUs measures the capacity of circulating mononuclear cells to form 
endothelial cells, the colonies may not directly arise from the CD34C stem cells. The 
exact phenotype of EPC-CFUs remains a matter of debate in part because the purity 
of CD34C cells used in the initial study was only 15%. (44) Peripheral blood contains 
several cell types that can differentiate into endothelial-like cells in vitro, including 
haematopoietic stem cells, mononuclear phagocytes (monocyte-macrophages), and 
mature endothelial cells. (49)  
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EPCs and hypertensive disorders in pregnancy 
Pregnancy involves adaptive changes in the maternal vasculature to ensure effective 
and adequate supply of nutrients to meet the increasing needs of the growing foetus. 
An up-regulation of endothelial function has been reported in pregnancy, resulting in 
vasodilatation as a result of increased release of vasodilators such as nitric oxide or a 
fall in the release of vasoconstrictors. EPCs have been detected among circulating 
mononuclear cells (MNCs) and in cord blood, and are thought to play an important 
role in vascular homeostasis. Bone marrow derived EPCs contribute to 
neovascularisation by vasculogenesis (de novo formation of blood vessels from 
precursors). The recruitment, mobilization and incorporation of bone marrow-derived 
EPCs have been shown to restore an intact endothelial lining. (50-53) 
Our knowledge regarding the mechanisms of adaptive endothelial changes of normal 
pregnancy their attenuation of failure in women who develop preeclampsia is rather 
incomplete. Populations of bone-marrow derived EPCs exist in the adult that are 
mobilized into the circulation by stimuli such as oestrogen and vascular endothelial 
growth factor, which can then differentiate into endothelial cells lining the lumen of 
blood vessels and/or release growth factors that act in a paracrine fashion to support 
the endothelium. EPCs are thus thought to function as a cellular reservoir to replace 
dysfunctional or senescent endothelial cells, and therefore may be critical to the 
overall health of the vascular endothelium. Data are emerging to suggest that the 
number of EPCs in the maternal circulation increases with normal pregnancy and that 
this change fails to occur in women with preeclampsia. Although speculative, it has 
been hypothesised that an excess of anti-angiogenic factors [including soluble fms-
like tyrosine kinase (sFlt-1) and soluble endoglin] interfere with nitric oxide-driven 
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mobilization or activity of EPCs in the maternal circulation, contributing to the 
widespread endothelial dysfunction underlying the clinical manifestations of 
preeclampsia. (54) 
As with CECs, the data on EPCs in hypertensive disorders of pregnancy are limited.  
(50, 53, 55-59) For example, Sugawara et al (50) examined the level of circulating 
EPCs throughout uncomplicated pregnancies (n=20) and assessed the correlation 
between serum oestradiol levels and the number of EPCs. The number of circulating 
EPCs was noted to increase gradually, paralleling the progression of gestational age. 
In addition, the number of EPCs correlates significantly with the level of serum 
oestradiol, suggesting their role in the regulation and maintenance of the placental 
development and vascular integrity during pregnancy. 
In a further study, Sugawara et al (53) found that the number of circulating EPCs was 
decreased in women with preeclampsia (n=8) compared with normotensive pregnant 
women (n=7) (median, 10.0 vs. 34.0 CFU; P <0.01). The rate of cellular senescence 
was significantly increased in patients with preeclampsia (33.9%) compared with that 
in controls (22.9%; P <0.05). Their patients with preeclampsia were divided into two 
subgroups: the CRP negative group (CRP <0.1 mg/dl; n=4) and the CRP-positive 
group (CRP >0.1 mg/dl; n=4). EPC CFU counts were markedly decreased in CRP-
positive patients compared with those in CRP-negative patients (5.0 and 25.0 CFU, 
respectively; P < 0.05).  They concluded that depletion and cellular aging of EPCs in 
patients with preeclampsia might be associated with endothelial dysfunction and 
could be affected by systemic inflammation.  
A study by Buemi et al (55) analysing and comparing the concentrations of EPCs 
during the 3 trimesters of normal pregnancy, gestational diabetes and hypertension 
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found a progressive increase in EPC levels in normal pregnancy. On the contrary they 
noted a fall in levels of CD34+ cells in the third trimester of women with gestational 
diabetes compared with the other groups. Further, although they found no significant 
differences between the diabetic and hypertensive patients for the percentage of cells 
expressing CD133 and VEGFR2, in both groups the percentage of 
CD133+/VEGFR2+ elements was significantly higher than in the healthy control 
subjects.  These findings suggest mechanisms regulating maternal vascular 
modifications during pregnancy as well as the different patterns of mobilization of 
endothelial progenitor cells during pathologic states in which endothelial disorders 
occur. Some of the other studies are summarised in Table 1.2.2. 
Endothelial dysfunction, Virchow’s triad & clinical implications 
Endothelial dysfunction is an important component of the Virchow’s triad. With its 
effects on the maternal vasculature during pregnancy as well as its long term effects 
on the cardiovascular health of women with gestational hypertension, a brief 
discussion on the relationship of endothelial dysfunction with the other components of 
the triad, i.e. abnormalities of haemorheology and turbulence at bifurcations and 
stenotic regions (‘abnormal blood flow’) and abnormalities in platelets as well as the 
coagulation and fibrinolytic pathways (‘abnormal blood constituents’) is noteworthy. 
(60) 
Although hypertension, in general, involves blood flow under high pressures, its 
complications such as myocardial infarction and stroke are thrombotic and not 
haemorrhagic, further confirming that it fulfils the pre-requisites of Virchow’s triad 
for thrombogenesis, leading to a pro-thrombotic or hypercoagulable state. Further, 
treatment of hypertension helps reverse some of these changes. (61, 62) 
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Figure 1.2.4 indicates a close relationship between thrombogenesis, atherogenesis and 
angiogenesis, the ‘vascular triad' (the Birmingham vascular triad), with the 
endothelium central to the processes. 
What are the clinical implications of this?  
The key adverse cardiovascular outcome clinically is myocardial infarction, 
particularly relevant in the current day, with many women having babies at an 
advanced age and being treated for risk factors for cardiovascular events, including 
hypertension, hypercholesterolemia, obesity, diabetes mellitus and family history of 
ischaemic heart disease.  Although pregnancy is not typically a risk factor for acute 
myocardial infarction, it increases the risk 3- to 4-fold. (63, 64) Many risk factors are 
unique for pregnancy-related acute myocardial infarction, with super imposed 
hypertension being an important one. (65, 66) 
The incidence of acute myocardial infarction has been reported to be 3 to 10 cases per 
100 000 deliveries. (66, 67) Although rare, acute pregnancy-related myocardial 
infarction can be associated with significant morbidity and mortality, both to the 
mother and the foetus, with a case fatality rate as high as 37%. (68) Even a single 
death due to acute myocardial infarction makes a substantial contribution to maternal 
mortality in view of an overall low rate (fewer than 12 women per 100 000). (69) 
Hence, a focussed approach by a multi-disciplinary team comprising of cardiologists, 
cardiology specialist nurses, obstetricians and mid wives is essential to managing 
pregnant women with hypertension in order to prevent cardiovascular morbidity and 
mortality and facilitate an uncomplicated and uneventful gestation and delivery. 
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Conclusions 
Hypertension in pregnancy is a spectrum of disorders, with a range of pathogenetic 
processes that may contribute to the varied manifestations of the maternal and foetal 
syndrome as a consequence. There is mounting evidence that endothelial dysfunction 
may well be central to and responsible for other irregularities in the maternal 
vasculature, with implications not only on the current gestation, but may potentially 
determine the future cardiovascular health status of the woman. 
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Figure 1.2.1: Circulating Endothelial Cells 
 
 
  
 
 
 
 
Figure 1.2.2: A typical Circulating Endothelial Cell isolated using the 
Immunobead Method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
31 
 
Figure 1.2.3a: Isolation of circulating endothelial cells by Flow Cytometry 
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Figure 1.2.3b: Gating strategy for endothelial / circulating progenitor cell 
enumeration with flow cytometry [CPCs, circulating progenitor cells] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CPCs, circulating progenitor cells.  The left hand FSC/SSC panel gates small 
lymphocyte-like cells, the centre panel identifies cells of low SSC but strongly 
expressing CD34, whilst the right hand panel show dual staining for CD133 and 
CD45. Thus CPCs are defined in the upper left quadrant as cells bearing CD34 and 
CD133, but not CD45. 
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Figure 1.2.4: Thrombogenesis, atherogenesis and angiogenesis in vascular 
disease: the Birmingham 'Vascular Triad' 
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TABLE 1.2.1: ENDOTHELIAL DYSFUNCTION AND PREGNANCY 
 
Study Patients (n) Markers studied Findings 
 
Canbakan et al (40) Preeclampsia (20) 
Hypertensive pregnant women 
(15) 
Normotensive pregnant women 
(15) 
Healthy non-pregnant controls 
(15) 
 
CECs, Homocysteine 
levels 
CECs elevated in women with preeclampsia  
compared with other groups [p < 0.0001] 
Nadar et al (41) Pregnancy induced hypertension 
(36) 
Normotensive pregnant women 
(36) 
Plasma vWf, E-selectin,  
thrombomodulin 
Significantly higher levels of plasma vWf (p=0.003), E-
selectin (p=0.001) and thrombomodulin (p=0.01) in women 
with pregnancy induced hypertension compared with 
normotensive controls 
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TABLE 1.2.2: ENDOTHELIAL PROGENITOR CELLS AND PREGNANCY 
 
Study 
 
Patients (n) Findings 
Sugawara et al (50) Uncomplicated pregnancies (20) Gradual increase in EPCs with progression of gestational age, with 
significant correlation with serum oestradiol levels 
Sugawara et al (53) Preeclampsia (8) 
Normotensive pregnant women (7) 
Circulating EPCs decreased in preeclampsia (p<0.01) 
EPC Colony Forming Units (CFU) counts markedly reduced in C-
reactive protein (CRP) positive patients (p<0.05) 
Buemi et al (55) Normal pregnancy (7) 
Gestational diabetes (7) 
Hypertensive pregnancy (7) 
Progressive increase in EPCs with gestational age 
Significantly lower CD34+ cells in gestational diabetes 
Significantly higher CD133+/VEGFR2+ in the diabetic and 
hypertensive groups 
 
Kwon et al (56) Severe preeclampsia (15) 
Normotensive controls (30) 
Significantly low EPCs in cord blood, umbilical cord plasma free 
vascular endothelial growth factor (VEGF) in severe preeclampsia 
compared to control group (p=0.009 & 0.04 respectively) 
Xia et al (57) Preeclampsia (14) Significantly reduced placental/ foetal EPCs and in vitro cultivated 
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Normotensive controls (10) EPCs in preeclampsia (p<0.001); inverse correlation of EPCs with cord 
blood levels of soluble fms-like tyrosine kinase 1 (sFlt-1), suggesting a 
decrease and dysfunction of placental/foetal circulating EPCs in pre-
eclampsia 
Savvidou et al (58) Normal singleton pregnancies (24) 
Normal twin pregnancies (21) 
Non-pregnant controls (8) 
Lower levels of EPCs noted in both the pregnant groups compared 
with non-pregnant controls, with a fall in levels with progression of 
gestational age (p=0.001 and 0.002 respectively) 
Lin et al (59) Preeclampsia (12) 
Normal pregnancy (12) 
EPC CFUs fourfold lower in preeclampsia compared with controls 
(p<0.005); elevated maternal plasma sFlt-1 (p< 0.0001) & reduced 
placental growth factor (PlGF) (p< 0.01) in preeclampsia, with no 
correlation with CFU-EPC counts. 
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1.3. Angiogenesis and apoptosis in hypertension in pregnancy 
 
The causes of most cases of hypertension during pregnancy remain unknown, although one of 
the first hypotheses focused on abnormal vascular reactivity and the over-production of 
vasoactive substances such as angiotensin II by the foetal/placental system (1, 2). Subsequent 
hypotheses predicted a role for factors such as endothelial cell activation, nitric oxide and 
misaligned trophoblast invasion (5-8). More recently, it has been suggested that abnormalities 
in angiogenic growth factors (e.g. vascular endothelial growth factor [VEGF], angiopoietin, 
and more recently, angiogenin) and apoptosis may be important (9-13).  
This chapter aims to provide an overview of current literature and concepts relating 
abnormalities in angiogenesis and apoptosis and the hypertensive disorders in pregnancy.   
Angiogenesis in pregnancy 
Normal intrauterine foetal development is dependent on adequate nutrient and substrate 
supply. Vasodilatation and development of new vessels both enable the adaptation of the 
uterine vasculature to the rising needs of the foetus. Angiogenesis is the process of 
neovascularisation from pre-existing blood vessels in response to hypoxia or substrate 
demands of tissues, and as such is a complex biological process comprising many steps that 
are precisely regulated by several molecules (15, 16). An initial step is the vasodilatation of 
the pre-existing vessel and formation of vesiculo-vacuolar organelles in the endothelial cells. 
The most important effector for this step is VEGF (70). Subsequently, vessel destabilization 
and matrix degradation occur, as perivascular stroma needs to be remodelled. Angiopoietin 2 
and proteases (such as chymases and matrix metallo-proteinases) are involved in this step. 
Endothelial cell proliferation and migration along a gradient of chemotactic agents then 
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proceeds through the disintegrated basement membrane into the remodelled and softened 
perivascular space (18). Specific mitogens of endothelial cells in this step are VEGF, 
angiopoietins, and fibroblast growth factor, epidermal growth factor, CXC-chemokines and 
insulin-like growth factor type 1, which induce the proliferation of several types of cells. This 
leads to lumen formation and vessel stabilization, by the migrated endothelial cells first 
forming a monolayer and then tube-like structures with surrounding mesenchymal cells and 
vascular smooth muscle cells. Different forms of VEGF and integrins have been implicated in 
this step (71). In the pregnant uterus, the endometrium, decidua and placenta are sources rich 
of angiogenic growth factors. Angiogenic process is initiated by growth factors such as basic 
fibroblast growth factor (bFGF), VEGF, or placental growth factor (PlGF) (20, 21). Whilst 
the role of these growth factors is established, others, such as angiogenin, may also be 
important.  
Angiogenin  
Angiogenin is a member of the ribonuclease (RNase) super family. The RNases are enzymes 
of innate substrate specificity, but divergent functional capacities, whose distinct structure 
confers  on angiogenin an endothelial binding motif, which it combines with its endonuclease 
enzyme activity and produces a potent stimulus for blood-vessel formation (22). 
Physiologically, angiogenin is also induced during inflammation, exhibiting wound healing 
properties as well as microbiocidal activity and conferring host immunity. Markedly high 
levels of angiogenin can be found in the circulation without proliferative impact. Angiogenin 
(or RNase 5) is a 14 kDa soluble protein, first isolated from the culture medium conditioned 
by colon carcinoma (HT-29) cells (72). The 123 amino acid chain and corresponding 
nucleotide sequences of angiogenin show 33% sequence identity and 65% homology with 
pancreatic RNase 1 (RNase A) (73). The tertiary structure of angiogenin still contains many 
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of the tertiary facets of peptide folding as seen in RNase 1, with the conservation of all key 
alpha helices and beta sheets (74). 
Eight members have been identified in the RNase super family, and whilst each has distinct 
biological effects, all share a common enzymic ribonucleolytic activity on RNA (75). In the 
case of angiogenin, RNase activity is directed towards 28S and 18S rRNA with the major 
products being 100–500 nucleotides in length (76). Evolutionary analysis of the angiogenin 
lineage from non-mammalian species suggests that angiogenin and RNase 4 (closest family 
member to angiogenin) represent the most ancient forms of the RNase super family (77). 
Recently, it has been established that angiogenin acts as an endogenous microbicidal agent 
against systemic bacterial and fungal pathogens (78), extending a role for innate immunity for 
the rest of the RNase super family. 
Angiogenin is present in plasma, in normal subjects, in a concentration of about 250–360 
µg/L (77). During human development, angiogenin has been detected in organs such as heart 
(in a foetus at 19 weeks), spleen (foetus at 19 and 20 weeks), lung (foetus at 19 week and 
adults), liver (foetus at 20 week and adult), colon, prostate, breast, brain, retina, melanocyte 
and foreskin (only in adults)(73, 79-81). However, angiogenesis does not take place 
continuously in all tissues, at all stages, as angiogenin-mediated angiogenesis requires a 
catalytic substrate and a cell surface receptor. Angiogenin expression is stimulated by the 
RNA that is likely to be released during apoptotic and necrotic cell damage in wound healing. 
The source of plasma nucleic acids is likely to relate to the phagocytotic activity of 
macrophages on dead cells (82). 
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Angiogenin in pregnancy 
The human placenta is one of the best in vivo models of physiological angiogenesis. 
Trophoblast cells invade the placental bed leading to remodelling of the spiral arterioles into 
maximally dilated low resistance vascular channels, which enables a high flow volume to the 
utero-placental bed (83). Hypoxia is a stimulus to increases the expression of mRNA and 
secretion of angiogenin in trophoblasts, at least in a human placenta experimental model. (83). 
Angiogenin levels increase from 150 to 250 ng/mL between weeks 10 and 40 in 
uncomplicated pregnancies (84), and during the first four postnatal days, there is a rapid 
increase in maternal serum angiogenin levels following healthy full-term pregnancies (85).  
Angiogenin probably has an important role in normal vascular development, as angiogenin 
levels are significantly decreased in patients with highly pathologic Doppler flow findings, 
compared with healthy pregnancies (84). Of note, pre-eclamptic patients who delivered low 
birth weight infants had higher levels of angiogenin than those who delivered infants with 
normal birth weight (85). 
Pavlov et al (86) studied the expression of angiogenin in situ and in vitro, using the human 
term placenta as a model of physiological angiogenesis. Angiogenin was immunodetected by 
light and transmission electron microscopy, and its cellular distribution was established by 
double immunolabelling with a panel of endothelial cell markers. Angiogenin 
immunoreactivity was detected in villous and extravillous trophoblasts, the trophoblast 
basement membrane, the endothelial basal lamina, foetal blood vessels, foetal and maternal 
red blood cells, and amnionic cells. Villous cytotrophoblasts, isolated and differentiated in 
vitro into a functional syncytiotrophoblast, expressed and secreted angiogenin. Their data 
suggested that, in human placenta, angiogenin has a role not only in angiogenesis but also in 
vascular and tissue homeostasis, maternal immune tolerance of the foetus, and host defences.  
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Angiogenin has been studied alongside VEGF by three groups. Shaarawy et al (87) recruited 
71 pregnant women with pre-eclampsia and 20 normotensive pregnant controls, finding 
maternal serum VEGF and angiogenin levels were significantly increased in cases of mild and 
severe pre-eclampsia compared to controls. This increase was positively correlated with 
elevated systolic and diastolic blood pressure, as well as abnormal Doppler velocimetry, and 
low birth weight. Their findings suggested a possibility of vascular reactivity and endothelial 
disturbance in pre-eclampsia, with measurement of these angiogenic factors in maternal 
serum as biomarkers for the assessment of the severity of the disease and of foetal outcomes. 
Lassus et al (88) measured VEGF and angiogenin in umbilical cord blood from 14 foetuses 
with erythroblastosis or alloimmune thrombocytopenia and at birth from 28 preterm foetuses, 
from 42 healthy term foetuses, and from 24 term foetuses born to mothers with insulin-treated 
diabetes, noting a significant correlation between VEGF and angiogenin levels. Gestational 
age correlated with both VEGF and with angiogenin, and VEGF levels were found to be 
lower in foetuses born to diabetic mothers than in the healthy term foetuses, although this 
difference was absent for angiogenin. Thus they found a developmental increase in 
concentrations of VEGF and angiogenin in umbilical cord plasma during the last trimester of 
gestation. The lower umbilical cord VEGF levels in term foetuses born to mothers with 
diabetes compared with those of healthy mothers may be secondary to abnormal foetal 
vascular development in diabetic pregnancies. Canbakan et al have (40) reported lower levels 
of angiogenin and VEGF in 38 normal and 38 hypertensive pregnancies compared to 50 non-
pregnancy. In the hypertensive pregnancies, angiogenin was not significantly different at 15 
weeks of pregnancy compared to 30 weeks implying low levels are present early and are 
fixed. However, although these studies are informative, it is clearly far too early to determine 
whether or not angiogenin has more to offer than does VEGF, in either clinical or 
pathophysiological matters.  Table 1.3.1 summarises the major studies in this field. 
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Apoptosis 
Apoptosis, the process of programmed cell death, has been implicated in the pathophysiology 
of pre-eclampsia (41). A working hypothesis states that inappropriate apoptosis of 
cytotrophoblast cells leading directly to poor vascularity and thus poor placentation, pre-
eclampsia and foetal problems (42-44). The Fas/Fas ligand (Fas/FasL) system is one of the 
main apoptotic pathways and is expressed in immune as well as non-immune cells, including 
trophoblasts (45).  Its expression and function respond to changes in the microenvironment 
and play a pivotal role in controlling cell proliferation and tissue remodelling. CD95 (Fas) is a 
type I membrane protein of 45 kDa that belongs to the TNF receptor family of proteins. FasL, 
a type II membrane protein of 37 kDa, belongs to the TNF and CD40 ligand family of 
proteins. Fas is widely expressed in many tissue types; in T and B cells, it is present 
constitutively in low levels on the surface of resting cells and its expression is enhanced 
following lymphocyte activation. In contrast to Fas, the expression of FasL is reported to be 
more restricted and often requires cell activation. The binding of the Fas receptor by FasL 
results in downstream activation of a cascade of intracellular proteolytic enzymes ending in 
apoptosis (89). 
The Fas/FasL system and pregnancy 
There is a considerable literature base demonstrating a role for Fas/FasL in pregnancy, many 
of which highlight regulated physiological apoptosis as part of an immunological response to 
the foetus (48-51).  For example, some suggest a role for complex reversible molecular 
mechanisms including intra-decidual T cell tolerance that occur during and soon after 
implantation of the conceptus (89). There is also evidence for endothelial cell and smooth 
muscle cell apoptosis driven by Fas/FasL (53, 54).  
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Aberrations in the Fas/FasL system have also been implicated in disorders of pregnancy (55-
58), including pre-eclampsia. The importance of the trophoblast in the pathophysiology of 
pre-eclampsia is clear, with reports of increased apoptosis of the extra villous trophoblast in 
the placental bed and villous trophoblast. The increased apoptosis may be secondary to an 
increase in trophoblast sensitivity to Fas-mediated apoptosis or an increase in material 
presented to a normally functioning cytotrophoblast/ syncytiotrophoblast system (59-63). The 
higher proliferation rate introduces more material into the syncytiotrophoblast via fusion and 
the multinucleated layer increases its apoptotic release of material to counterbalance this. 
Hence the increase in apoptosis is perhaps a sign of higher turnover of villous trophoblast 
secondary to an adaptive process. An increase in Fas expression coupled with decreased FasL 
expression in the villous trophoblast has been demonstrated (90). Serum from preeclamptic 
women has been shown to reduce trophoblast viability, and that effect seemed to be related to 
changes in trophoblast sensitivity to Fas-mediated apoptosis (91). Further, deportation of 
villous trophoblast debris directly into the maternal circulation is implicated in the genesis of 
an exaggerated intravascular maternal inflammatory response in pre-eclampsia (66). This may 
part-explain the link between the aberrant placentas and activated maternal endothelium seen 
in pre-eclampsia. 
Whilst the Fas/FasL system operates between cells, soluble forms of both molecules may be 
found in the plasma (67, 68). Indeed, it has been suggested that soluble Fas protects from 
apoptosis (69). Whilst low soluble Fas is present in normal pregnancy compared to non-
pregnancy, an increase in soluble Fas has been noted in pre-eclampsia (92) although Kuntz et 
al have been unable to confirm this increase (73). We have (93)found no differences in 
soluble Fas between 50 non-pregnant women, 20 normal pregnancies and 20 hypertensive 
pregnancies (free of pre-eclampsia) at early or late stages of the gestation.  However, changes 
in soluble Fas are not specific for pre-eclampsia (75-77). Parallel data on soluble Fas ligand 
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are weak. Laskowska et al (72) reported no change in soluble Fas ligand in 11 cases of pre-
eclampsia compared to 12 healthy normotensive pregnancies, whilst Kuntz et al (73) found 
raised levels in 20 pre-eclamptic hypertensive pregnancies compared to 18 controls.  .  The 
purpose of measuring the molecules in different disease groups of course hopes to identify a 
putative disease marker that would have predictive value. The experiments outlined above 
provide limited opportunity to do so, and far larger studies are required for the degree of 
sensitivity and specificity concerned. Nevertheless, Hsu et al have speculated that apoptosis 
triggered by the release of soluble Fas ligand may be an important pathophysiological 
process(92).  Table 1.3.2 summarises major studies. 
Conclusions 
Angiogenesis and apoptosis are two important physiological processes that occur in the 
maternal vasculature, and angiogenin and the sFas/sFas ligand system are worthy of 
investigation. However, whether or not they provide fresh insights when compared to the 
VEGF (79-81), remains to be determined Significant abnormalities in both these processes are 
described in pregnancies complicated by diseases such as pre-eclampsia, but whether they are 
mere associations or causative in nature is unclear at present. Studies exploring their role in 
the pathogenesis of conditions including hypertension in pregnancy, before the development 
of pre-eclampsia/eclampsia and changes in their markers with progression of gestation would 
be helpful in understanding them better in the future.  
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TABLE 1.3.1: ANGIOGENESIS AND PREGNANCY 
 
Study Patients (n) Markers studied Findings 
Shaarawy et al (87) Pre-eclampsia (71) 
Normotensive pregnant women 
(20) 
 
VEGF, angiogenin • Significantly raised VEGF and angiogenin levels in 
mild and severe pre-eclampsia. 
• Positive correlation between their raised levels and 
poor bio-physical score, abnormal umbilical and 
uterine artery Doppler velocimetry and low birth 
weight. 
Nadar et al (94) Pregnancy induced hypertension 
(PIH) (69, pre-eclampsia, n=35) 
Normotensive pregnant women 
(64) 
Non-pregnant controls (30) 
VEGF, angiopoietins 
(Ang-1, Ang-2), and 
their soluble receptors 
Flt-1 (sFlt-1) and Tie 2 
(sTie-2)  
• Significant differences in plasma VEGF, Ang-1, 
Ang2, sFlt-1 and Tie-2 between the study groups. 
• Ang-1 highest in the pre-eclampsia group (p<0.001) 
• Ang-2 highest in the normotensive pregnant group 
(p=0.018) 
• Plasma Tie-2 highest in the PIH group 
• VEGF levels significantly different between the pre-
eclampsia group and the PIH group (p<0.05) 
Kupferminc et al Pre-eclampsia (19) VEGF • Significantly raised VEGF levels in pre-eclampsia 
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(95)  Normotensive pregnant women 
(19) 
(p<0.001); 
• Positive correlation between VEGF and systolic and 
diastolic blood pressures in the preeclamptic group (r 
=0.56; p= 0.01 and r=0.48; p = 0.037, respectively). 
Baker et al (96) Pre-eclampsia (27) 
Non-proteinuric PIH (15) 
Normotensive pregnant women 
(36) 
VEGF • VEGF levels below the lower limit of detection.  
• The proportion of detectable levels higher in the pre-
eclampsia group (7/27) than in the normotensive 
group (1/ 36, P < 0.05). 
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TABLE 1.3.2: APOPTOSIS AND PREGNANCY 
 
Study Patients (n) Markers studied Findings 
Laskowska 
et al (97) 
Pre-eclampsia (11) 
Hypertensive 
pregnant women 
(12) 
 
Maternal and 
umbilical serum 
soluble Fas and 
Fas ligand 
• Increased maternal and 
umbilical vein serum sFas and 
increased umbilical vein serum 
sFasL levels in the study group 
in comparison with the control 
group (p<0.001). 
Kuntz et al 
(98) 
Pre-eclampsia (20) 
Normotensive 
pregnant women 
(18) 
Paired maternal 
and umbilical cord 
blood serum 
soluble Fas and 
Fas ligand 
• Soluble FasL levels higher in 
paired maternal and umbilical 
cord blood (CB) sera of 
hypertensive gestations (p < 
0.01). 
• Soluble Fas levels similar 
between the groups.  
• Surface expression of FasL 
lower on maternal (p < 0.01) 
and CB (p < 0.05) neutrophils 
from affected gestations, 
whereas surface Fas expression 
lower on maternal (p < 0.02), 
but not CB, neutrophils and 
lymphocytes. 
Hsu et al 
(92) 
Pre-eclampsia (34) 
Normotensive 
pregnant women 
(34) 
Serum soluble Fas 
levels 
• Higher serum soluble Fas 
levels in preeclamptic women 
(p < 0.001). 
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1.4. The extra-cellular matrix in hypertension in pregnancy 
 
Matrix metalloproteinases (MMPs) are a family of endopeptidases that degrade the components 
of the extracellular matrix (ECM) and contribute to the remodelling and physiological 
homeostasis of the ECM. They depend on the zinc and calcium for their activity and are 
regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). A balance between 
MMPs and TIMPs has been suggested to play an important role in vascular remodelling, 
angiogenesis and vasodilatation of both the uterine and systemic vasculature during normal 
pregnancy. Consequently, any imbalance between the two can result in alterations in the 
maternal vasculature and promote the development of the spectrum of hypertensive disorders of 
pregnancy. The altered balance can also cause other vascular diseases including abdominal aortic 
aneurysm, varicose veins, etc. Both MMP-9 and TIMP-1 levels have been shown to be altered in 
hypertension in pregnancy.(99, 100) 
Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of nine or more highly homologous Zn (++)-
endopeptidases that collectively cleave most of the constituents of the extracellular matrix. They 
belong to a large family of proteases known as the metzincin super family and are involved in 
the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), 
and chemokine/cytokine in/activation. (101) MMPs are also thought to play a major role on cell 
behaviours such as cell proliferation, migration (adhesion/dispersion), differentiation, 
angiogenesis, apoptosis and host defence. They are distinguished from other endopeptidases by 
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their dependence on metal ions as cofactors, their ability to degrade extracellular matrix, and 
their specific evolutionary DNA sequence.(102) 
MMPs are produced by many tissues and cell types including the vascular cells. They are either 
secreted from the cell or anchored to the plasma membrane and are often bound with heparin 
sulphate glycosaminoglycans on the cell surface. Metalloelastase (MMP-12) is expressed mainly 
in macrophages and is essential for macrophage migration (103). MMP-19 was identified by 
cDNA cloning from liver and as a T-cell–derived auto antigen from patients with rheumatoid 
arthritis (RASI) (104, 105). 
The MMP family 
The MMP family consists of 26 enzymes, 23 of which have been found in humans. They are 
divided into 6 groups as follows (106) 
1. Collagenases [MMP-1, -8, -13, and -18 (Xenopus)] cleave interstitial collagens I, II, and 
III at a specific site three-fourths from the N-terminus, releasing ¼ and ¾ length 
fragments. They also cleave other ECM and non-ECM molecules. 
2. Gelatinases, including gelatinase-A (MMP-2) and gelatinase-B (MMP-9) digest 
denatured collagens (gelatins).  
3. Stromelysins, including stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10). MMP-3 
has similar substrate specificity but higher proteolytic efficiency as compared to MMP-
10. 
4. Matrilysins [matrilysin-1 (MMP-7) and matrilysin-2 (MMP-26, endometase)]. 
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5. Membrane-Type MMPs (MT-MMPs) [type-I transmembrane proteins MT1-, MT2-, 
MT3-, and MT4-MMP (MMP-14, -15, -16, and -24), and the 
glycosylphosphatidylinositol (GPI)-anchored proteins MT5-, and MT6-MMP (MMP-17 
and -25)]. MT1-MMP can digest type-I, -II, and III-collagen and other components of 
ECM, and can activate proMMP to MMP. 
6. Others, including MMP-11, -12, -19, -20, -22, -23, and -28. 
Effects of MMPs 
MMPs have been postulated to inhibit vascular smooth muscle contraction, although the exact 
mechanisms are unclear. They are also suggested to have a variable influence on angiogenesis. 
On one hand, MT1-MMP, MMP-2, -7, -9 and stromelysin-3 mRNA have been suggested to play 
an important role in angiogenesis, particularly in relation to tumor invasion and metastases. An 
augmentation in MMP activity is positively linked to an increase in metastatic and angiogenic 
potential of tumours. They can enhance angiogenesis by multiple mechanisms, including 
enabling the detachment of pericytes from vessels undergoing angiogenesis, releasing ECM-
bound angiogenic growth factors, by exposing cryptic proangiogenic integrin binding sites in the 
ECM, by generating promigratory ECM component fragments and by cleaving endothelial cell-
cell adhesions.(106) 
MMPs during pregnancy 
MMPs have been suggested to promote decidualization, an important prerequisite for successful 
implantation. Studies have shown endometrial production of proMMP-2, -3, -7, -9, and active 
MMP-2 (107). Further, MMP-26 mRNA is expressed in the mouse uterus during the oestrous 
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cycle and early pregnancy and may play a role in the cycling changes in the uterus during the 
estrous cycle and in embryo implantation (108). 
MMPs are probably involved in placental remodeling throughout pregnancy. MMP-2 
expression/activity in extravillous trophoblasts, and MMP-9 in villous cytotrophoblasts has been 
described in first trimester human placental tissue. The former has been observed in full term 
placental tissue, whereas the gelatinase activity was decreased or completely lost. The gelatinase 
activity was marked in early, but not term cytotrophoblasts. Invasive ability of early 
cytotrophoblasts was inhibited by TIMP-2 and anti-MMP-2 antibody. These data suggest that the 
invasive ability of trophoblasts may be regulated by gelatinases, especially MMP-2 (109). This is 
supported by reports of polarized release of MMP-2 and -9 from cultured human placental 
syncytiotrophoblasts (110). The studies emphasize the importance of temporal regulation of 
MMPs to perform specific functions during the gestation period.(111) 
Increases in the plasma levels of MMPs have also been detected during normal pregnancy, 
suggesting their role in the pregnancy-associated changes in vascular function (111). 
Further, MMPs probably play a role in the uterine artery remodeling during pregnancy and may 
help maintain uterine blood flow in late pregnancy. Continued elevated levels of some MMPs 
post-partum may contribute to vessel regression and return to a non-pregnant physiological state 
(112). 
MMPs and hypertension 
Hypertension is associated with vascular remodeling characterized by rearrangement of vascular 
wall components including ECM proteins. Recent studies have examined the role of MMPs and 
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TIMPs in the vascular remodeling associated with hypertension. A clinical study in 44 
hypertensive patients and 44 controls demonstrated that the plasma levels and activities of MMP-
2, MMP-9, and TIMP-1 are increased in hypertensive patients, which may reflect abnormal ECM 
metabolism (113). Other studies have shown different results and demonstrated that the plasma 
concentrations of active MMP-2 and MMP-9 are depressed in patients with essential 
hypertension. Also, a 6 month treatment with amlodipine normalized MMP-9 but not MMP-2 
plasma concentrations (114). These studies suggested a role of abnormal ECM metabolism in 
hypertension, and raised the interesting possibility that antihypertensive treatment may modulate 
collagen metabolism. In addition, it demonstrates that MMPs from the same family can have 
significant and different effects in vascular function and disease processes. 
Other studies examining the expression/activity of MMPs in internal mammary artery specimens 
obtained from normotensive and hypertensive patients undergoing coronary artery bypass 
surgery have shown that that not only MMP-1 and MMP-9, but MMP inducer and activator 
proteins are down regulated in the hypertensive state, which may result in enhanced collagen 
deposition in hypertension (115). 
Experimental studies have also examined whether hypertension is associated with vascular 
remodeling and changes in the vascular tissue expression/activity of MMPs and the effects of 
MMP-9 during the progression of hypertension. It has been suggested that MMP-9 activation is 
associated with a beneficial role early on in hypertension by preserving vessel compliance and 
alleviating BP increase. 
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MMPs and preeclampsia 
MMP-mediated vascular remodeling has been suggested to play a role in the pathogenesis of 
preeclampsia (111). MMP-2 is elevated in the plasma of women with preeclampsia (116) as well 
as in those who subsequently develop preeclampsia (117). Changes in circulating MMP-9 and 
TIMP-1 and -2 levels have also been observed in gestational hypertension (118). Increased net 
MMP-2 activity probably contributes to endothelial dysfunction that is central to the 
pathophysiology of preeclampsia (117). However, recent studies testing the hypothesis that 
proteases intrinsic to syncytiotrophoblast microvillous membranes (STBM) are the cause of the 
in vitro endothelial changes detected gelatinase activity and showed that it was due to MMP-9. 
Its presence has been confirmed by immunohistocytochemistry. Studies have, however, 
suggested that the effect of STBM on endothelial cells is unlikely to be caused by intrinsic 
proteases (119).The placenta has been suggested to be the source of the increased plasma MMPs. 
Low levels MMP-1, -9 and -3 were detected in extracts from the wall of human umbilical cord 
artery. MMP-2 is the main collagenolytic enzyme in umbilical cord artery (UCA) wall (both 
latent and active form). Preeclampsia is associated with a reduction in those MMPs content in 
comparison to control UCA. Hence the decrease of MMP content and activity in the umbilical 
cord artery may reduce the breakdown of collagen in the arterial wall. The accumulation of 
collagen with simultaneous reduction in elastin content in the UCA may reduce the elasticity of 
arterial wall and decrease the blood flow in the foetus of women with preeclampsia (120).Studies 
have examined the secretion of MMP by cultured human decidual endothelial cells from normal 
and preeclamptic pregnancies. MMP-9 and TIMP1 levels were similar between the two cell 
types; however, the basal and stimulated secretion of MMP-1 was markedly higher in normal 
compared with preeclamptic endothelial cells. It was suggested that the lower MMP1 expression 
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of decidual endothelial cells from preeclamptic women may inhibit endovascular invasion by 
cytotrophoblasts. These findings may, at least partly, explain the relative failure of trophoblasts 
to invade maternal decidual blood vessels in preeclamptic pregnancy (121). 
MMPs and clinical disease 
MMPs have been suggested to play a role in the pathogenesis of other related conditions 
including atherosclerosis and destabilisation of the atherosclerotic plaque, its rupture and 
coronary stenosis; formation of abdominal aortic aneurysm (AAA) and development of varicose 
veins. (106). There has been recent research looking into their role in left ventricular remodelling 
in hypertension as well as in the pathogenesis of end-organ damage secondary to hypertension 
(122-124). 
Tissue inhibitors of metalloproteinases 
The MMPs are inhibited by specific endogenous tissue inhibitor of metalloproteinases (TIMPs), 
which include four protease inhibitors: TIMP-1, TIMP-2, TIMP-3 and TIMP-4. They bind 
MMPs in a 1:1 stoichiometry and their expression is regulated during development and tissue 
remodelling. 
A number of inhibitors of MMPs with potent anti-angiogenic activity are in early stages of 
clinical trials, primarily to treat cancer and cancer-associated angiogenesis. Initial clinical trials 
using MMP inhibitors as cancer treatments did not demonstrate efficacy in terms of reducing 
tumour progression partially because most trials were done in patients with advanced stage 
disease, when the tumour vasculature is already well-established, and also due to the fact that 
MMPs play multiple roles in both angiogenesis and tumour progression.  
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Experimental studies have suggested significant effects of doxycycline in reducing the 
progression of AAA. There is also widespread interest in developing MMP inhibitors for the 
prevention of atherosclerotic plaque rupture. The MMP inhibitors, EDTA and 1,10-
phenanthroline, as well as recombinant TIMP-1, reduced the activities of MMP-1, -2, -9 and -3 
which co-localized with regions of increased immunoreactive MMP expression, i.e., the 
shoulders, core, and microvasculature of the plaques (125).  
MMPs and TIMPs in hypertension in pregnancy 
Some of the studies looking at levels of MMP and TIMP are summarised in table 1.4.1. 
Conclusions 
The extracellular matrix is an important component of the vascular biology of the maternal 
vasculature and plays a significant role in the maintenance of the internal milieu in pregnancy. 
Alterations in the relative concentrations of its constituent enzymes and their inhibitors have 
profound effects on the homeostatic mechanisms that control blood pressures in the mother.  
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TABLE 1.4.1: MMPs AND TIMPs IN PREGNANCY 
 
Study Patients (n) Markers 
studied 
Findings 
Tayebjee et 
al (118) 
Gestational 
Hypertension , GH 
(23) 
Normotensive 
pregnant women (30) 
Non pregnant healthy 
women (28) 
 
MMP-9. TIMP-
1, TIMP-2 
• Significantly higher MMP-9 and 
lower TIMP-1 as well as MMP-
9/TIMP-1 ratios in normotensive 
pregnant women compared with 
non-pregnant controls. 
• Higher TIMP-2 levels in the GH 
group. 
• Negative correlation between 
MMP-9 and MMP-9/TIMP-1 
with age and diastolic blood 
pressure. 
Palei et al 
(126) 
Gestational 
Hypertension , GH 
(26) 
Preeclampsia (27) 
Normotensive 
pregnant women (30) 
Non pregnant healthy 
women (30) 
 
MMP-2, MMP-
9, TIMP-1, 
TIMP-2 
• Higher pro-MMP-9 levels and 
higher pro-MMP-9/TIMP-1 
ratios in women with GH. 
• No significant differences in pr-
MMP-2 levels. 
Montagnana 
et al (100) 
Preeclampsia (14) 
Normotensive 
pregnant women (37) 
Non pregnant healthy 
women (21) 
 
MMP-2, MMP-
9, TIMP-1, 
TIMP-2 
• Significantly raised MMP-2 and 
TIMP-1 levels in preeclampsia 
compared with other two groups. 
• MMP-9 and TIMP-2 levels 
higher in the normotensive 
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pregnant group compared with 
non-pregnant controls. 
• Positive correlation between 
MMP-9 levels and gestational 
age in normotensive pregnant 
women. 
Lavee et al 
(127) 
Gestational 
Hypertension , GH 
(26) 
Normotensive 
pregnant women (30) 
 
Amniotic 
MMP-2, TIMP-
2 
• Mean amniotic MMP-2 & TIMP-
2 higher in women with GH; 
significantly higher MMP-2 
levels in those who eventually 
developed preeclampsia. 
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Section 2: MD Proposal 
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The MD proposal was submitted at the time of registration to the University of Birmingham.  
The included proposal is an amended version appropriate to the thesis. 
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Aim: 
To study the different aspects of vascular biology (angiogenesis, apoptosis, haem oxygenase 
system and extra cellular matrix turnover) in the aetiopathogenesis of hypertension in pregnancy, 
with particular emphasis on their relationship(s) to endothelial damage/dysfunction (circulating 
endothelial cells and progenitor cell pathophysiology).  
Background: 
Hypertension is a widely prevalent condition with an estimated 972 million affected 
worldwide.(128) It is the most common medical problem encountered during pregnancy, 
complicating 6-8% of pregnancies, with chronic hypertension being a primary disorder in most 
cases.  Hypertensive disorders in pregnancy (defined in Appendix 1) are a leading cause of 
maternal mortality worldwide and increase perinatal mortality five-fold even in developed 
countries. (129) It is also one of the areas of clinical practice that has been studied extensively, 
yet remains less well understood. 
The endothelium has many vital and diverse physiological roles, such as regulation of blood 
vessel tone, (130, 131) permeability, metabolism and haemostasis. Impairment of endothelial 
function manifests clinically as oedema, hypertension, abnormal vasoconstriction and 
hypercoagulability. Impaired endothelial function has also been found to be associated with 
hypertension, diabetes mellitus and heart failure (regardless of aetiology) (132-135), although 
whether it occurs as a cause or consequence is undetermined. Endothelial function is closely 
linked to inflammation and thrombosis as inflammatory cytokines induce expression of pro-
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coagulants such as tissue factor. Hence, understanding endothelial function is likely to be a key 
to modifying risk factors of hypertensive disorders of pregnancy and their sequelae.  
Circulating endothelial cells (CECs) are a novel way of determining endothelial cell damage. 
CECs are thought to be detached from the inside of vascular structures and enter the circulation 
as a result of vascular injury. Raised CECs have been shown in myocardial infarction, unstable 
angina and critical limb ischemia.(20, 37, 136) They are also increased in other diseases 
associated with endothelial injury, including septic shock, sickle cell crisis, ANCA (anti-
neutrophil cytoplasmic antibody) small vessel vasculitis, thrombotic thrombocytopenic purpura 
(TTP), systemic lupus erythematosus (SLE) and Behcet’s disease, with an increase in their 
numbers used for assessment of vascular damage and a marker of disease activity. (20)  We are 
only aware of one study that has investigated CECs in pregnancy and pregnancy induced 
hypertension.  In this small study, Wang et al(137) found a significant increase in CECs (p<0.01) 
in women with pregnancy induced hypertension compared to those with normal blood pressure.  
It is unclear if CECs are simply apoptotic or represent a stimulus to repair/angiogenesis, in 
relation to hypertension in pregnancy. 
Generation of vessels is classified into angiogenesis and vasculogenesis, the former being the 
sprouting of capillaries from pre-existing vessels (e.g. tumours and embryos) and the latter being 
the development of blood vessels from in situ differentiating endothelial cells and is essential for 
the growth of blood islands and differentiation of the systemic vascular network in the 
embryonic yolk sac and foetus. Endothelial cells are generated in the periphery of blood islands 
from bone marrow-derived endothelial progenitor cells (EPCs). (138, 139)  Indeed, EPCs are 
found in pregnant women and are thought to play important roles in vascularisation of the uterine 
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endometrium at embryo implantation and placentation during pregnancy, as angiogenesis is 
increased in the endometrium from implantation through early pregnancy.(140, 141)  
Abnormalities of EPCs may be involved in the pathogenesis of preeclampsia, with previous 
studies revealing that primitive EPCs are present in most pregnant women during the second 
trimester.(140)  Their numbers increase gradually and parallel gestational age in normal 
uncomplicated pregnancies,(50) but decrease in women with preeclampsia, with increase in the 
rate of cellular senescence. (53) 
Further, serum/plasma markers associated with neo-vascularisation and vascular growth 
(angiogenic factors), apoptosis and extra cellular matrix turnover are hypothesized to play an 
important role in endothelial dysfunction. New vessel formation during human placental 
development occurs by vasculogenesis and angiogenesis, the latter by elongation in the term 
placenta.  Many angiogenic factors are available; the most commonly studied being vascular 
endothelial growth factor (VEGF) and more recently, angiogenin.  
Angiogenin is a 14-kDa secreted protein with angiogenic and ribonucleolytic activities, and is 
one of the most potent inducers of neovascularisation in experimental models in vivo. 
Angiogenin is present throughout the foetal vascular tree and is expressed not only by these cells, 
but by all trophoblastic cells. The physiological role of angiogenin expression is believed to be 
related to endothelial-like functions assumed by the syncytiotrophoblast in direct contact with 
maternal blood. Successful pregnancy requires a harmonious and co-ordinated development of 
the vascular and trophoblastic components of the villi to form a functional area of exchange 
between the maternal and foetal blood, this is probably supported by angiogenin expression.(86)  
Shaarawy et al (87) studied 91 pregnant women (20 normotensive healthy pregnant controls, 55 
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women with mild preeclampsia and 16 with severe preeclampsia) in the late third trimester (34-
40 weeks) and compared angiogenin and vascular endothelial growth factor (VEGF) in these 
three groups. Serum angiogenin levels were significantly elevated along with serum VEGF 
levels in women with mild and severe preeclampsia (p<0.001). These elevations were 
significantly associated with foetal poor biophysical profile scores and negatively correlated with 
infant birth weight in preeclamptic patients (p<0.01). 
The haem oxygenase system is involved in vascular tone, regulating anti-inflammatory and anti-
apoptotic responses as well as reducing oxidative stress and subsequent tissue damage in several 
organ systems. Haem oxygenase -1 (HO-1) is a 32-kDa inducible form of the haem oxygenase 
enzyme, found in most tissues of the body and expressed in high concentrations in the liver and 
spleen, areas of high erythrocyte turnover; HO-2 is a 36-kDa constitutive form and HO-3 the 
least characterized and least active isoform. The haem oxygenase system and their catalytic 
products are linked to several vital tasks of pregnancy such as placentation, placental 
hemodynamic control and antioxidant protection and hence are thought to play an important role 
in the progression of a healthy pregnancy to term. (142) HO-1 has been found to be reduced 
significantly in placentae from pregnancies complicated with preeclampsia that probably 
predisposes to placental injury, maternal endothelial cell activation and contributes to the 
development of preeclampsia and its complications.(143) Further, HO-1 is suggested to have a 
complex role in angiogenesis by mechanisms that are less understood presently (144, 145) and 
reduced HO-2 has been suggested to account for increased vascular resistance and oxidative 
injury to the trophoblast, resulting in endothelial dysfunction and apoptosis in pregnancy induced 
hypertension.(146) 
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The Fas-Fas ligand (FasL) system is one of the major pathways for the induction of apoptosis in 
cells and tissues. (147)  Fas (CD95) is a type I membrane protein of 45 kDa that belongs to the 
tumour necrosis factor (TNF) super family and Fas L, a type II membrane protein of 42 kDa 
belongs to the TNF and CD40 ligand family. Fas is expressed widely in many tissues, T and B 
cells and in human trophoblast throughout gestation.(148) It is abnormally activated in diseases 
associated with impaired immune tolerance or chronic inflammation.(98) Previous studies have 
shown that maternal serum soluble Fas/ Fas ligand levels are elevated in pregnancies 
complicated by hypertension, preeclampsia and the HELLP (haemolysis, elevated liver enzymes 
and low platelets) syndrome, a severe variant of preeclampsia.(97, 98, 149) The increased 
expression of Fas in trophoblasts is hypothesized to promote apoptosis of placenta in 
preeclampsia.(148) 
The matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are also hypothesized 
to be responsible for the development of endothelial dysfunction, contributing to the 
pathophysiology of hypertension in pregnancy and preeclampsia.(117)  Matrix 
metalloproteinases (MMPs) are zinc-based catalytic enzymes responsible for maintaining tissue 
allostasis. They are active at neutral pH and can catalyse the normal turnover of extra cellular 
matrix (ECM) macromolecules such as the interstitial and basement membrane collagens, 
proteoglycans as well as accessory ECM proteins such as fibronectin. Members of the MMP 
family include the "classical" MMPs, the membrane-bound MMPs (MT-MMPs) the ADAMs (a 
disintegrin and metalloproteinase; adamlysins) and the ADAMTS (a disintegrin and 
metalloproteinase with thrombospondin motif). There are more than 20 members in the MMP 
and ADAMTS family including the collagenases, gelatinases, stromelysins, some elastases and 
aggrecanases. MMP activity is regulated by a group of endogenous proteins, called, tissue 
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inhibitor of metalloproteinases (TIMPs) that bind to active and alternative sites of the activated 
MMP.(118, 150) However, previous studies investigating MMP-2, MMP-9 and TIMP-1 and 
TIMP-2 levels in pregnancy and preeclampsia have obtained contradictory results.(111, 118, 
151) For example, a comparison of the levels of MMP-9, TIMP-1 and TIMP-2 in pregnant 
women revealed a significantly higher circulating MMP-9 and lower TIMP-1 levels in 
normotensive pregnant women compared to the non-pregnant. TIMP-2 was found to be higher in 
those with gestational hypertension. Consequently, MMP-9/TIMP-1 ratio was highest in the 
normotensive pregnant women and lowest in the non-pregnant control group. MMP-9/TIMP-2 
ratio was highest in the normotensive pregnant group and lowest in the gestational hypertension 
group. (118) 
In summary, there is as yet no report of a comprehensive assessment of endothelial dysfunction 
in pregnancy. The aim of this study is to assess indices suggestive of endothelial activation-
dysfunction-damage and their relationship to angiogenesis, apoptosis and extra cellular matrix 
turnover.   
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Hypotheses to be tested: 
This thesis aims to address three specific, focussed hypotheses pertaining to the vascular biology 
of hypertension in pregnancy. 
1. When compared to normotensive pregnant women and healthy, non-pregnant women, 
hypertensive pregnant women have significant abnormalities of circulating endothelial 
cells and endothelial progenitor cells.  
a. EPCs are positively correlated to indices of angiogenesis (angiogenin, haem 
oxygenase) and negatively correlated to indices of apoptosis (Fas/ Fas Ligand), 
endothelial damage/dysfunction (CECs, von Willebrand factor (vWf)) and 
MMP/TIMP levels (as indices of extra cellular matrix turnover). 
b. CECs are positively correlated with indices of apoptosis, endothelial damage/ 
dysfunction and MMP/TIMP, and negatively correlated with indices of 
angiogenesis.  
2. Sequential changes of these indices with progression of pregnancy (gestation weeks 12-
14, 28-32) and post-partum are significantly different between hypertensive pregnant 
women and normotensive pregnant women.  
3. Abnormalities of these indices can be related to pregnancy outcomes (birth weight, 
Ponderal index, placental weight). 
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Study Design: 
1. Cross Sectional Study: 
Pregnant women with pregnancies complicated by high blood pressure and its effects presenting 
to the antenatal hypertension clinic/ day assessment unit or the maternity wards M1/ M2 at City 
Hospital between 28 and 34 weeks, were compared with matched normotensive pregnant women 
and normal healthy non-pregnant controls. All patients had demographic details including age, 
sex, race, weight, blood pressure, co-morbid cardiovascular conditions recorded. 
Inclusion criteria: 
• Women aged between 18 and 45 years 
• Pregnant women with normal (< 140/ 90 mm Hg and not on anti-hypertensive treatment) 
and high blood pressure (≥ 140/90 mm Hg or  < 140/90 mmHg whilst on anti-
hypertensive agents) 
• Women able and willing to provide informed, written consent 
Exclusion criteria: 
• Women >45 years  
• Presence of potential confounders- significant co-existing medical conditions, such as 
heart disease, renal disease, malignancy, vasculitis, connective tissue disease, recent 
major surgery or trauma 
• Unable or unwilling to provide informed, written consent 
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2. Prospective Study: 
Pregnant women attending the antenatal hypertension clinic had blood samples taken at booking 
[12-14 weeks of gestation], 28-34 weeks gestation and at approximately 6-8 weeks post-partum. 
Blood samples were measured on each occasion to assess their relation with gestational age and 
determine their prognostic value.  
Endpoints for this study 
One or more of the following: 
• Development of pre-eclampsia/eclampsia 
• Complications of pregnancy and/ or labour as consequence of high blood pressure 
• All cause maternal and/or foetal mortality 
• Adverse maternal or foetal outcome as a consequence of the high blood pressure or its 
effects (intra-uterine growth retardation, congenital anomalies, spontaneous miscarriages, 
intra-uterine deaths, oligohydramnios) 
The design of the study was made by me with the support and advice from my supervisors. Any 
modifications during the course of the project were also made by me. 
The recruitment of the study patients as well as healthy pregnant and non-pregnant controls was 
wholly made by me. 
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Laboratory assays: 
1. 15 to 20 ml of blood was taken from subjects into 1 citrate, 2 EDTA and 1 serum tubes, 
using a 21 G butterfly needle®.  Blood was venesected into 1 citrate, 2 EDTA and 1 
serum Vacuette ® tubes. 1 EDTA bottle (usually the last tube filled) provided the whole 
blood samples needed for CEC analysis using immunomagnetic beads (1 ml) and EPC 
analysis using flow cytometry (1 ml). All other samples were centrifuged at 3000rpm for 
20 minutes to obtain plasma/serum which was aliquoted and frozen at -80ºC for batch 
analysis. 
2. CECs and progenitor cells were measured using whole blood collected in a fluoridated 
tube.  
a. CECs were quantified using an established Immunobead method.41 These cells 
were separated using magnetic beads coated with monoclonal antibodies against 
CD146 and repeated washing with PBS buffer.  
b. Progenitor cells were quantified by Flow Cytometry. Peripheral mononuclear 
cells were obtained and stained for FACS analysis with antibodies to CD34, CD 
45, and CD 133.  
3. Citrated plasma was then aliquoted and frozen at -70°C for batch analyses using ELISA 
for the following parameters: 
a. Angiogenin, HO-1 
b. soluble Fas, soluble Fas ligand 
c. von Willebrand Factor, sFlt-1 
d. MMP-9 and TIMP-1 
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All laboratory methods are established in the University of Birmingham Centre for 
Cardiovascular Sciences laboratory. 
All the lab work, including storing of samples, preparation of samples for analysis of CECs and 
CPCs and the ELISAs were performed by me, with the appropriate training on the above 
techniques provided by Dr A Blann and Mr B Balakrishnan. 
The analysis of samples for CECs and CPCs was performed by blinding the samples before 
preparing them and then subsequent unblinding. Most of this was by obtaining a mix of samples 
from the three study groups on the days of recruitment and blinding the subject details using 
appropriate coding/ marking of samples. Further confirmation and validation of CEC numbers 
was made by seeking a second count by Dr S Jessani, my co-researcher, who was blinded to the 
source of the sample (the study groups).  
Data analysis and statistics 
For a power of 80% and 5% level of significance, based on the studies above and the limited data 
currently available, we aimed to recruit at least 40 patients in each group, for our cross-sectional 
analysis and at least 20 patients for the longitudinal study.  
Following a test of statistical normality, data was expressed as mean (± standard deviation, SD) or 
median (inter-quartile range, IQR), as appropriate.  Non-categorical data distributed normally have 
been analysed by one way ANOVA, and paired samples analysed using t test. Non-parametric data 
were analysed by Kruskal Wallis or by the Mann-Whitney U test. Correlations were sought by 
Spearman’s rank method. Categorical data (sex, age) were analysed by the chi-squared test. A 
probability of ≤0.05 was considered as statistically significant. 
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Data collection, storage and analysis as well as statistical tests were performed by me, using SPSS 
15 software, after obtaining training on the statistical methods relevant to the study from Dr. A 
Blann and Dr. D A Lane. The graphical representation of the data was made using Graph Pad Prism 
4 software. 
Ethical Considerations 
The study was conducted in accordance with the declaration of Helsinki. Ethical approval was 
obtained from the Sandwell and West Birmingham Local Research Ethics Committee. Written 
informed consent was obtained from all patients. 
The application process for approval of the study as well as appropriate amendments to the study 
was made by me (with guidance from my supervisors) with both the local Research and 
Development department as well as from Sandwell and West Birmingham Local Research Ethics 
Committee. 
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3.1 Pharmacovigilance: Angiotensin converting enzyme inhibitors 
and angiotensin receptor blockers in pregnancy 
 
 
Introduction 
Chronic hypertension (blood pressure > 140/90mmHg) in women of childbearing age is usually 
mild hypertension, with the 10-year cardiovascular risk being very small, and cardiovascular 
events such as strokes and myocardial infarctions are extremely uncommon. In such low-risk 
women, there is little information on the level of blood pressure at which antihypertensive 
therapy should be prescribed, that is, in which the benefits of treatment outweigh the hazards. 
Current guidelines stress the importance of considering long-term cardiovascular risk rather than 
the absolute level of blood pressure alone prior to considering treatment and recommend treating 
patients with blood pressures that persistently exceed 160/100 mmHg (152-154). The British 
Hypertension Society guidelines suggest the use of angiotensin-converting enzyme inhibitors 
(ACE-Is) as first choice in patients younger than 55 years, with angiotensin receptor blockers 
(ARBs) reserved for patients intolerant of them (154). All guidelines, as well as national 
formularies and pharmaceutical company data sheets, however, advise that these agents should 
not be prescribed in pregnant women or women of child bearing age. Some women may, have an 
unplanned pregnancy while taking ACE-Is or ARBs, and in older women of childbearing age the 
coexistence of type 2 diabetes may prompt specialists in diabetes or general practitioners to 
prescribe these agents because of their reported benefits in reducing diabetic nephropathy. 
There have been sporadic reports of developmental anomalies, particularly of the heart, skull and 
central nervous system in babies whose mothers were taking ACE-I at the time of conception 
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(155-159). One epidemiological study from Tennessee involving 29 507 infants reported ‘major’ 
congenital malformations in 7.1% of infants in which the mother had been taking an ACE-I in 
the first trimester of pregnancy. This contrasted with major anomalies in 2.0% of infants exposed 
to other antihypertensive drugs in pregnancy and 2.6% in which the mother took no 
antihypertensive drugs (160). The possibility that the ARBs may also be associated with 
developmental malformations has been raised by sporadic reports, and an analysis of 64 
published cases in which unfavourable outcomes were reported in 42% (161, 162). To take 
things further, we  investigated the possible hazards of ACE-Is and ARBs in pregnancy and 
analysed pregnancy outcomes in all mothers attending our antenatal hypertension clinic, who had 
conceived while taking these agents or who had had them prescribed in early pregnancy. 
Methods 
The City Hospital, Birmingham, serves about one-third of the population of the city of 
Birmingham, England with a catchment area comprising about 300 000 people. However, as the 
hospital has a large obstetric service and Neonatal Intensive Care Unit, mothers are also referred 
in from surrounding areas. Between 1 June 1977 and 30 April 2009, all women attending the 
weekly specialist antenatal clinic who had hypertension in early pregnancy were referred to a 
special weekly hypertension clinic to be seen jointly by a physician and an obstetrician. Data 
were collected prospectively in all 1078 hypertensive mothers referred to the clinic, with 
reference to their hypertension, the drugs they received and the obstetrical outcomes. After 
delivery, all babies are examined by a paediatrician before being discharged home. A total of 94 
pregnancies were identified in which the mother had been or was taking either an ACE-I or an 
ARB. We have outcome data in 91 (96.8%) of these.  
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Results 
Ninety-four pregnancies (including one twin pregnancy) were encountered in women who were 
receiving angiotensin-blocking drugs at the time of conception, and there were a further two 
women who had been prescribed an ACE-I in early pregnancy, one by their family doctor and 
one by a junior doctor in the diabetic clinic because of microproteinuria. In all women, these 
drugs were discontinued at the first visit to the clinic and in 48 (50%) these it was not considered 
necessary to substitute an alternative antihypertensive drug in the short term. Three women, all 
on ACE-Is, were lost to follow-up, having been delivered elsewhere (two in Pakistan). Outcome 
data are therefore available in 91 pregnancies. 
Angiotensin-converting enzyme inhibitor pregnancies  
Outcome data were available in 71 pregnancies in 66 women. Their mean (SD) age was 34.9 
(4.9) years (range 19–44 years); 34 were South Asian, 22 were African Caribbean, 14 were 
European and one was Hispanic. Twenty mothers also had type 2 diabetes mellitus. The median 
interquartile range (IQR) duration of ACE-I use in pregnancy was 8.0 (6.0–13.0) weeks (range 
6–28 weeks). The drugs were lisinopril (39 pregnancies; mean dose 10.4 mg), ramipril (14; 6.7 
mg), enalapril (11; 18.8 mg), perindopril (4; 2 mg) and trandolapril, quinapril and captopril (one 
each; 2, 10 and 15 mg, respectively). 
Angiotensin receptor blocker pregnancies 
Outcome data were available in all 20 women, one of which had a twin pregnancy. Their mean 
(SD) age was 35.8 (5.3) years (range 23–46 years); eight were South Asians, 11 African 
Caribbeans and two Europeans. Four mothers also had type 2 diabetes mellitus. The mean 
  
76 
 
duration (IQR) of ARB use in pregnancy was 8.0 (6.0–10.0) weeks (range 5–18 weeks). The 
drugs were valsartan (7 pregnancies; mean dose 80 mg), losartan (5; 100mg), candesartan (4; 
6mg), irbesartan (2; 150mg), telmisartan (2; 80 mg) and eprosartan (one patient; dose not 
recorded). 
Outcomes 
In the 71 pregnancies in women taking an ACE-I, there were 59 (83.1%) live births, eight 
miscarriages before 20 weeks gestation, one termination of pregnancy and three intrauterine or 
early neonatal deaths in which no developmental malformations were detected (Table 3.1.1). Six 
babies (10.2%) were found to have developmental abnormalities. These were one small 
ventricular septal defect which had closed spontaneously by the age of 6 months, one mild 
sensorineural deafness, one mild microcephaly (head circumference below the second centile) 
whose development up to the age of 2 years was normal, one hypospadias not requiring early 
surgery, one umbilical hernia, in an African Caribbean baby, not requiring surgery and one mild 
congenital hypotonia. In the 20 pregnancies (21 babies) in women who conceived while taking 
an ARB there were two miscarriages, one intrauterine death and one neonatal death due to 
trisomy 13 (Patau syndrome) (Table 3.1.1). Two developmental defects were identified in the 
remaining 17 babies (one inguinal hernia not requiring surgery and one craniosynostosis with 
tower skull. At follow-up this child did have delayed milestones and learning difficulties. 
Discussion 
The interpretation of these data must be done with great care and the following limitations need 
to be considered before drawing conclusions. Although the antenatal clinic data were collected 
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prospectively and represents all women receiving ACE-Is or ARBs in pregnancy in a single large 
hospital, the numbers are small. There were only eight developmental anomalies which might be 
attributed to these drugs, although this represents 8.8% of all live births. Many of the anomalies 
(e.g., the ventricular septal defect and the hernias) were very common, trivial or self-limiting. 
Only one defect, the craniosynostosis, can be considered to be major. Our major developmental 
anomaly rate was therefore 1.1%. Our results are, therefore, in sharp contradiction to those of 
Cooper et al. in the United States (160). Our results for the use of ARBs are also in contrast to 
the findings of Velazquez-Armenta et al. (162). Examining current literature they reported 
outcomes in 64 pregnancies. In 27 of these there were unfavourable outcomes including 14 
(21.9%) developmental defects. This report may be affected by publication bias (i.e. the 
tendency of researchers to selectively publish adverse outcomes only). The patients attending our 
antenatal clinic were at high risk due to their age, ethnic origin and severity of hypertension. 
These characteristics would not be expected to cause developmental anomalies but might 
contribute to poor obstetrical outcomes. There were 10 miscarriages before 20 weeks gestation 
and five intrauterine or early neonatal deaths which were not due to structural anomalies. These 
numbers may reflect the high-risk status of the patients. The presence of concomitant diabetes 
might increase the risk of caudal regression syndrome. Major developmental defects were not 
encountered in the 24 diabetic patients in this study.  
Although many of our patients were at high obstetrical risk, their short-term cardiovascular risk 
is low. We suspect that many of the women were started on their antihypertensive therapy after 
only cursory assessment of their cardiovascular risk status. Many may not have really needed 
blood pressure-lowering drugs in the first place. When we stopped the ACE-Is or ARBs, it was 
only necessary to substitute another agent (in the short term at least) in 47.8%. Among those 
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women who genuinely do need antihypertensive drugs in pregnancy there is a therapeutic 
dilemma. In the early British Hypertension Society guidelines the other class of drugs 
recommended in pregnancy was the β-receptor blockers (152). However, there is a body of 
evidence that strongly suggests that these drugs, or at least atenolol, when used in early 
pregnancy, may cause intrauterine growth retardation (163, 164). Labetolol is licensed for the 
treatment of hypertension in pregnancy, but the need to take this drug multiple (two or three) 
times per day raises issues with compliance and limits its usefulness except in very high-risk 
pregnancies (165). Methyldopa is known to be safe in pregnancy but many clinicians are 
reluctant to use this drug for fear of causing postnatal depression, although, there are no reports 
of this adverse effect in the world literature. It is possible that some clinicians are prescribing 
antihypertensive drugs in pregnancy in the hope that this will prevent the development of 
superimposed preeclampsia. There is, however, no evidence that the treatment of hypertension in 
early pregnancy leads to any reduction in the incidence of preeclampsia (165, 166). The benefits 
of antihypertensive drug therapy in pregnancy are confined to the prevention of the development 
of more severe hypertension and to avoid hospital admission for preterm delivery (166). Another 
factor influencing the choice of antihypertensive drugs is the pressure to prescribe angiotensin-
blocking agents for patients with incipient or overt diabetic nephropathy (167). Twenty-two 
(23.9%) of our patients had type 2 diabetes and three of these had persistent proteinuria in early 
pregnancy. As previously mentioned, the ACE-I was started in pregnancy by clinicians in the 
diabetic clinic in one patient. Although the total number of pregnancies studied here is 
considerably smaller than the report by Cooper et al. (160), our pregnancy series has a number of 
strengths. All mothers were cared for by one clinician and, therefore, we are confident that this 
series includes all mothers on angiotensin-modulating drugs seen at one single large centre. In 
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addition, all babies were examined by a paediatrician or a paediatric specialist nurse before 
discharge home. Hence, it is very unlikely that any developmental anomalies went undetected. 
Ascertainment bias therefore does not explain why we have found fewer anomalies.  
In conclusion, while our data are largely reassuring, the use of angiotensin-blocking drugs in 
pregnancy and in women who are likely to conceive should be avoided until further large case 
series and case–control studies are reported. The fact that we have encountered 94 pregnancies in 
which the mother was receiving angiotensin blocking drugs strongly suggests that treatment 
guidelines and pharmaceutical company data sheets are frequently being ignored. 
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TABLE 3.1.1: OUTCOMES IN PREGNANT WOMEN TREATED WITH ACE-I OR 
ARB IN EARLY PREGNANCY  
Outcomes [n (%)] ACE-Is in early pregnancy ARBs in early 
pregnancy 
Miscarriage before 20 weeks gestation 8 (11.3) 2 (10.0) 
Termination of pregnancy 1 (1.4) 0 (0) 
Intrauterine or early neonatal death 
(no anomaly detected except trisomy 13) 
3 (4.2) 1 (5.0) 
Live births 59 (83.1) 19 (95.0)* 
Developmental malformations   
• None 53 (74.6) 17 (85.0)* 
• Small ventricular septal defect 1 (1.4) 0 (0) 
• Mild sensorineural deafness 1 (1.4) 0 (0) 
• Mild microcephaly 1 (1.4) 0 (0) 
• Mild hypospadias 1 (1.4) 0 (0) 
• Small umbilical hernia 1 (1.4) 0 (0) 
• Small inguinal hernia 0 (0) 1 (5.0) 
• Neonatal hypotonia 1 (1.4) 0 (0) 
• Craniosynostosis with tower skull 0 (0) 1 (5.0) 
Total 71 (100) 20 (100) 
* Includes one twin pregnancy. 
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3.2 Endothelial dysfunction and hypertension in pregnancy: 
Associations between circulating endothelial cells, circulating 
progenitor cells and plasma von Willebrand factor 
 
Introduction 
Hypertension in pregnancy, preeclampsia and eclampsia has been studied extensively, with 
abnormalities in placentation being implicated as a cause of these disorders. Current focus has 
been directed towards abnormalities in the maternal vasculature, including endothelial 
dysfunction and impaired repair as a probable cause for preeclampsia, with the latter also being 
implicated in the development of cardiovascular disorders in later life in these women. (168) 
This chapter explores the relationship between indices of endothelial dysfunction and 
hypertension in pregnancy.  
Circulating endothelial cells (CECs) are mature cells detached from the vascular intimal layer in 
response to a variety of insults and are defined phenotypically by the expression of endothelial 
markers (e.g. von Willebrand factor, VE-cadherin, CD146) together with the absence of the 
expression of leukocyte (CD45) and immaturity markers (CD133). Amongst these, CD146 has 
evolved as the most popular marker for their identification, being concentrated at the endothelial 
junction where it plays a plays a key role in the control of cell-cell cohesion, permeability and 
signalization (13, 15). Increased numbers of CECs are taken to imply vascular damage (19).  
Circulating progenitor cells (CPCs) are non-leukocytes derived from the bone marrow with 
proliferative potential that may be important in vascular regeneration with properties similar to 
embryonal angioblasts, at different stages of maturation, from early (vascular endothelial growth 
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factor receptor [VEGFR]/CD133+) to a more mature (VEGFR/CD34+) phenotype. CPCs are 
viable, can form colonies in vitro, have the capacity to differentiate into mature endothelial cells, 
and line the internal elastic membrane of the blood vessel. Hence, CPCs represent a subset of 
cells at varying stages of development present in the peripheral blood stream. (18, 42-44). It 
follows that as CECs reflect endothelial damage, and CPCs are mechanism to repair that damage, 
then the ratio of CECs to CPCs may have pathophysiological significance. Their number has 
been established as a biomarker of cardiovascular risk and is known to decrease with age.(169) 
Increased levels of von Willebrand factor (vWf), as are present in many cardiovascular, 
connective tissue and neoplastic diseases, are indicative of endothelial cell damage/dysfunction 
(170), although an increase in vWf during pregnancy is physiological (171). Nevertheless, raised 
vWf (41, 172, 173) and CEC levels (40, 174) have been previously demonstrated in pregnancy 
induced hypertension and preeclampsia, while altered endothelial progenitor cell levels have 
been shown in pregnancies complicated with diabetes and hypertension. (50, 53, 55, 58, 175) 
We hypothesised abnormal levels of circulating endothelial cells (CECs), circulating progenitor 
cells (CPCs) and plasma vWf in pregnant women with hypertension, when compared to non-
pregnant hypertensives and normotensive controls. We also hypothesised an altered balance 
between the degenerative and restorative processes, as determined by an altered CEC:CPC ratio.  
We tested this hypothesis on a cross-section study of women attending our antenatal 
hypertension clinic.  
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Methods 
The study group included pregnant women between 18 and 45 years with raised blood pressure 
(≥140/90 mm Hg) or normal blood pressure (<140/90 mm Hg) and on anti-hypertensive drugs.  
Collection of Blood Samples and Laboratory Methods, isolation of CECs and CPCs, and 
estimation of vWf levels has already been described. 
Power calculations and statistical analyses 
For a power of 80% and 5% level of significance, based on the limited data currently available, 
we aimed to recruit 30 patients in each group. Following a test of statistical normality, data were 
expressed as mean (± standard deviation, SD) or median (inter-quartile range, IQR), as 
appropriate.  Non-categorical data distributed normally were analysed by one way ANOVA, and 
paired samples using t test. Non-parametric data were analysed by Kruskal Wallis or by the 
Mann-Whitney U test. Correlations were sought by Spearman’s rank method. Categorical data 
(sex, age) were analysed by the chi-squared test. A probability of ≤0.05 was considered as 
statistically significant. A multiple regression analysis sought those indices likely to predict 
levels of CECs, CPCs and vWf. 
Results  
We recruited 38 hypertensive pregnant women, 40 normotensive pregnant women and 50 non-
pregnant healthy women as controls. The subject groups and controls were matched for age. The 
gestational age and parity were higher in the hypertensive pregnant women group (Table 3.2.1). 
As expected, both systolic and diastolic blood pressures were significantly higher in the 
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hypertensive pregnant group. Hypertensive pregnant women had significantly high CEC levels 
(2-fold compared with normotensive pregnant women and 4-fold compared with non-pregnant 
healthy controls). CPCs were raised in normotensive pregnant group compared with hypertensive 
pregnant and non-pregnant healthy controls; the CPC counts were lower in hypertensive 
compared with normotensive pregnant groups, but this did not reach statistical significance.  
CPC: CEC ratio was lower in hypertensive pregnant women compared with non-pregnant 
healthy controls (Table 3.2.1) (Figure 3.2.1).  
A negative correlation was noted between CPC: CEC ratio and BP (Spearman r = -0.30, p<0.005 
and r = -0.26, p<0.05, respectively). Both the pregnant women groups had significantly higher 
vWf levels than the non-pregnant controls. vWf correlated significantly with CEC levels 
(Spearman r = 0.39, p<0.0001) and CEC levels correlated with both systolic and diastolic BP 
(Spearman r = 0.28, p<0.005 and r = 0.31, p<0.001, respectively). Multiple linear regression 
analysis revealed hypertension in pregnancy as an independent predictor of CEC levels 
(p<0.0001). 
Discussion 
This study demonstrates a significant difference in the levels of CECs, CPCs and their ratios as 
well as vWf in hypertension in pregnancy prior to the development of pre-eclampsia. CECs were 
noted to be doubled in hypertensive pregnant women compared with normotensive pregnant 
women and four times that in non-pregnant controls. This is perhaps the first study looking at 
relationship between CECs and CPCs, and with vWf, and determining their ratios as a potential 
marker of imbalance between endothelial damage and repair in hypertension in pregnancy in the 
absence of preeclampsia. 
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Previous studies (40, 50, 53, 55, 58, 174, 175) have investigated CECs and CPCs in 
preeclampsia. An increase in CECs, confirming endothelial dysfunction in preeclampsia has 
been described, and our data confirm this finding. However, variable results have been obtained 
with CPCs. Some studies have described a reduction in CPCs, with higher levels in normal 
pregnancies that parallel the progression of gestation, suggesting an important role they may play 
in regulating and maintaining placental development and vascular integrity during pregnancy. 
Matsubara et al noted that CPC number in peripheral blood did not differ significantly between 
preeclampsia and normal pregnancy, although their proliferation was significantly increased in 
preeclampsia (175). In contrast to the above findings, Savvidou et al noted an actual decrease in 
CPC levels in normal pregnancy (58).  Our finding of increased CPCs in normal pregnancy adds 
to the uncertainty as to the role of these cells. We suggest that the raised CPCs in the healthy 
pregnant women in our study may reflect a general mobilisation from the bone marrow, perhaps 
under the influence of vascular endothelial growth factor (176), known to be increased in 
pregnancy (177).  Alternatively, raised CPCs may be associated with increased placental 
angiogenesis (178).  
vWf, a robust and well-established marker of endothelial damage/dysfunction, has been 
previously shown to be raised in pregnancy induced hypertension and preeclampsia (41, 170-
173) . Of these, Nadar et al (41) noted that plasma vWf was significantly raised in pregnancy 
induced hypertension along with other markers of endothelial activation. The study by Molvarec 
et al (172) demonstrated significantly higher vWf in preeclampsia compared to healthy pregnant 
and non-pregnant controls. We are unaware of any other study correlating vWf and CEC levels 
in hypertension in pregnancy, and their correlation underlines their value as markers of vascular 
damage. In addition, hypertension in pregnancy and preeclampsia has been recognised as a risk 
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factor for the development of hypertension in later life (1). Endothelial dysfunction and its 
markers (including CECs and vWf) are associated with a variety of inflammatory states as well 
as hypertension and cardiovascular disease states. (170, 179) Our data therefore confirms and 
extends other work on vascular dysfunction  in pre-eclampsia.(174)  
The above findings suggest the presence of a dynamic process of endothelial damage due to the 
shearing effects of a hyper dynamic circulation and attempts at regeneration towards restoring 
endothelial integrity and preventing the development of complications as a result of failure in 
these mechanisms and raised blood pressures. A corollary to this would be to determine who 
amongst both the hypertensive group and the normotensive group develop preeclampsia-
eclampsia and adverse pregnancy outcomes and hypertension and cardiovascular disease in later 
life. 
The clinical implications of the alterations in CEC: CPC ratio remains to be seen in larger 
studies. Further, the role of CEC: CPC ratio as a biomarker to predict endothelial dysfunction 
would require the development of a single test that is reliable, validated and easily reproducible 
in clinic or at the bedside.  
Limitations 
This study is limited by its cross-sectional design and relatively small sample size. Although the 
subject groups were matched with respect to age, the gestational ages and parities of the 
hypertensive pregnant women was higher. However, whether this has had any influence on our 
findings is rather unclear. Further, the antigenic definition of CPCs is highly variable across 
literature, with no universally accepted profile as yet (18, 40, 42-44, 50, 53, 55, 58, 174, 175, 
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180). Thus, it is not possible to definitively extrapolate current data and apply this to all 
progenitor cell populations. Finally, our study has analysed CPCs using only one laboratory 
technique looking at cell counts and has not taken into account cell function – i.e. the potential 
for CPCs to reproduce and integrate into the endothelium. Such assessment is usually based on 
cell culture experiments, but is an important characteristic to define CPCs. Further studies, 
longitudinal in design and involving larger sample sizes are required to clearly establish a 
possible aetiological association between an imbalance in endothelial damage and repair and the 
development of complications and adverse outcomes in hypertension in pregnancy. 
In conclusion, hypertension in pregnancy is characterised by abnormalities in the vascular 
endothelium, with abnormal CECs and vWf that correlate with blood pressure.  This may reflect 
dysfunctional processes that are counteracted with reparative attempts at restoring endothelial 
integrity.   
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TABLE 3.2.1: LEVELS OF BLOOD PRESSURE, vWF, CECs, CPCs AND CEC:CPC 
RATIOS BY GROUPS 
 
 
 
 
Mean (SD) 
Hypertensive 
Pregnant  
(n=30) 
Normotensive 
Pregnant  
(n=39) 
Non-pregnant 
healthy controls 
(n=43) 
p-value 
Age (years) 31.9 (5.5) 28.8 (5.8) 30.6 (8) 0.146 
Gestational Age (weeks) 30.3 (2.9) 26.7 (3.4) NA < 0.0001 
Median (IQR) Parity 2 (0-3) 1 (0-2) 0 (0-1) < 0.0001 
SBP (mm Hg)  133 (17) 112 (9) 118 (9) < 0.0001 
DBP (mm Hg)  87 (11) 66 (6) 75 (9) < 0.0001 
vWf (IU/dL) § 157 (34) * 156 (27) * 139 (37) < 0.0001 
CEC levels (/ ml) §  4 (2-5) * 2 (1-2) 1 (0-2) < 0.0001 
CPC levels (/ ml) 296 (145-548) 370 (250-494) * 254 (144-378) < 0.05 
CPC:CEC ratio 78 (41-172) † 194 (101-370) 120 (78-230) < 0.05 
 
Between group analyses by ANOVA with Tukey post hoc test and Kruskal Wallis test with 
Dunn’s post hoc test, as appropriate  
 
*Significantly higher than healthy controls  † Significantly lower than healthy controls 
§
 Hypertensive pregnant women (n=38); Normotensive pregnant women (n=40); Non-pregnant 
healthy controls (n=50). Data are presented as mean (SD), median (IQR) or absolute numbers. 
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Figure 3.2.1: Circulating Endothelial Cell levels (CECs), Circulating Progenitor Cell levels 
(CPCs), Circulating CEC:CPC ratios and von Willebrand Factor levels by groups 
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(c) Circulating Progenitor Cell : Circulating Endothelial Cell ratios  
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HBP: Hypertensive pregnant women; NBP: Normotensive pregnant women; HC: Non-pregnant 
healthy controls 
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3.3 Angiogenin, Haem oxygenase 1, soluble Flt, VEGF in 
hypertension in pregnancy 
 
Introduction 
Key aspects of the development of various pathologies in pregnancy, including hypertension in 
pregnancy, pre-eclampsia and eclampsia, are changes in the release of various growth factors and 
their cell bound receptors. These include vascular endothelial growth factor (VEGF), its receptor 
Flt-1 on endothelial cells {a soluble form (sFlt-1) of which can be found in plasma (96, 181-
183)} and angiogenin. (84, 87, 184) Whilst VEGF and sFlt-1 have been extensively studied in 
clinical hypertension, and also in women with hypertension in pregnancy (94, 185, 186), there 
are no reports of angiogenin in women whose pregnancy is complicated by hypertension. Haem 
oxygenase-1 (HO-1) is an enzyme involved in the breakdown of haem to biliverdin, iron and 
carbon monoxide. As the latter is, like nitric oxide, a vasodilator, HO-1 may have a role in 
regulating blood vessel tone and thus hypertension. (187, 188) Notably, there are data suggesting 
a link between HO-1, sFlt-1 and VEGF, and thus, angiogenesis.  (189-192) This has generated a 
hypothesis that impaired regulation of HO-1 may be important in the pathophysiology of pre-
eclampsia. (142, 193) However, there are no data on HO-1 in the hypertension of pregnancy. 
We hypothesised altered levels of angiogenin and HO-1 in the plasma of women whose 
pregnancy is complicated by hypertension. As comparator molecules, we chose VEGF and sFlt-
1, (189-193) but also von Willebrand factor (vWf). This pro-coagulant was included because it is 
a product of the endothelium, is known to be raised in normal pregnancy, and also in 
hypertension (41, 170, 171) as well as in pre-eclampsia. (172, 173) We tested our hypothesis on 
a cross-sectional study of women attending a specialist antenatal hypertension clinic, a standard 
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antenatal clinic, and in healthy non-pregnant women. Samples were obtained from hypertensive 
women on two occasions to determine whether or not there were changes as their pregnancy 
progressed. 
Methods 
The study and control groups have been described earlier. 
Collection of Blood Samples and Laboratory Methods 
Blood samples were collected into sodium citrate and were centrifuged within 30 min at 1,500g 
for 20 min at 4°C. Plasma was collected and stored at -70°C until batch processing by ELISA for 
vWf (Dako-Cytomation, Ely, UK), VEGF, sFlt-1, angiogenin (R&D Systems, Abingdon, UK) 
and haem oxygenase-1 (HO-1, Stressgen, Ann Arbour, USA). The intra and inter-assay co-
efficient of variation was <5% and <10%, respectively for all assays. Lower limits of detection 
were vWf 10 IU/dL, VEGF 0.05 ng/mL, sFlt 1.0 ng/mL, angiogenin 20 ng/mL and HO-1 0.3 
ng/mL. 
Power calculations and statistical analyses 
Based on existing literature on growth factors in normal and pre-eclamptic pregnancy (84, 87, 
94, 183, 184, 186) we hypothesised a change in VEGF (our test statistic) of 50% in normal 
pregnancy and of 66% in hypertensive pregnancy compared to levels in non-pregnancy 
(modelled median 100 units, interquartile range [IQR] 67-176 units). For a 1-beta power of 80% 
and alpha 5% giving ANOVA p=0.001, we needed 35 patients in each pregnant group and 50 
controls. In hypothesising a change of 33% at 2 time points, paired samples from 20 women are 
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required for p=0.005 if levels are increased in 12 women, are unchanged in 3, and fall in 5 
women. For extra confidence, we recruited slightly in excess in the pregnancy groups. Following 
a test of normality, data were expressed as mean (standard deviation, SD) or median (IQR) and 
analysed by one way ANOVA or the Kruskal Wallis test respectively. Intergroup differences 
were sought by Tukey’s post hoc test. Data 2 time points was analysed by paired t test or 
Wilcoxon’s test. Correlations were sought by Spearman’s rank method. Categorical data were 
analysed by chi-squared tests. A two-tailed probability of <0.05 was considered significant.  
Results  
We recruited 38 hypertensive pregnant women (of whom 23 were studied at 2 time points), 38 
normotensive pregnant women and 50 non-pregnant healthy women as controls.  
VEGF was lower in the hypertensive pregnant women compared with the non-pregnant women, 
with no difference in sFlt-1, but the sFlt-1/VEGF ratio was higher in both pregnant groups 
compared with the non-pregnant group. Angiogenin was lower in normal pregnancy compared 
with non-pregnancy and hypertension-pregnancy, whilst HO-1 was also lower in normal 
pregnancy compared with non-pregnant controls. There was no difference in HO-1 between the 
pregnant hypertensive women and the non-pregnant women (Table 3.3.1) (Figure 3.3.1). With 
the exception of vWf and VEGF, there were no differences in any marker or blood pressure at 
the 2 presentations on average 15 weeks apart (Table 3.3.2). 
Angiogenin and vWf correlated significantly in the hypertensive and normotensive pregnant 
women (r=0.35, p=0.03 and r=0.34, p=0.04), respectively, but in the non-pregnant women the 
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correlation was not significant (r=0.13, p=0.367). None of the plasma indices correlated with 
age, duration of pregnancy or blood pressure. 
Discussion 
The contribution of the current study is to examine the role of plasma angiogenin and HO-1 in 
the hypertension of pregnancy, focussing on blood pressure, VEGF, and its receptor sFlt-1. We 
found low angiogenin in normal pregnancy, and that these low levels were partially restored in 
hypertension compared with levels in healthy non-pregnant women. Low levels of HO-1 in 
normal pregnancy were also reinstated by the hypertension of pregnancy. There were no changes 
in angiogenin or HO-1 at weeks 15 or 30 of 23 hypertensive pregnancies. Neither angiogenin nor 
HO-1 correlated with any other index, except that angiogenin and vWf correlated significantly in 
the hypertensive and normotensive pregnant women but not in the non-pregnant women. 
There is evidence of the involvement of angiogenin and HO-1 in angiogenesis and in 
hypertension, both conditions where the endothelium is crucial. These 2 conditions combine in 
the hypertension of pregnancy, the most severe form of which is pre-eclampsia, which also 
implicates growth factor dysregulation (6-26, (194-196). Data on angiogenin and VEGF in pre-
eclampsia are conflicting. For example, Reuvekamp et al (184) reported low VEGF but no 
difference in angiogenin in 30 women with pre-eclampsia (mean 524 ng/ml) compared with 30 
non-pregnant controls (mean 670 ng/mL), although p=0.058 implies a type 1 (false negative due 
to small number) artefact. However, they suggest that deficient angiogenic growth factors may in 
part explain the shallow placentation found in pre-eclampsia. Shaarawy et al (87) reported raised 
angiogenin and VEGF that correlated with systolic and diastolic blood pressure in 71 pre-
eclamptics vs. 20 normotensive pregnancies. They hypothesise that raised growth factors could 
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confirm the existence of vascular reactivity and endothelial disturbance in pre-eclampsia. With 
modest power we found that in normal pregnancy there was a significant reduction of angiogenin 
to 64% of non-pregnant levels, but that in hypertensive pregnancy this reduction was to a 
significant 87%.  
Notably, in both pregnant groups, angiogenin correlated with vWf, the gold standard index of 
endothelial damage/dysfunction (170), known to be raised in normal pregnancy (171) and 
hypertension, (197) but there was no correlation in non-pregnant women. Interestingly, vWf was 
not further raised in hypertensive pregnant women compare with pregnant women, despite the 
presence of an addition stimulus to increase vWf in the former. The vWf/angiogenin relationship 
does not necessarily imply that raised angiogenin is related to endothelial damage/dysfunction, 
but it does clearly imply some relationship, the pathophysiological significance of which is 
unknown. Although angiogenin is present in human umbilical vein endothelial cell tissue culture 
supernatants, but not platelets, it may also arise from other cells. (198)  
Blood obtained at 2 time points in 23 hypertensive women showed no change in angiogenin or 
HO-1, implying that the abnormalities in these markers develop at an early stage of pregnancy 
and then persist. vWf increased during pregnancy as expected, (171) and although VEGF also 
increased, the statistical significance of this rise is small and so at risk of bias. However, 
interpretation is marred by the lack of data at 2 time points in normal pregnancies. 
HO-1 is an enzyme involved in iron metabolism, but whose product, carbon monoxide, may be 
important in blood pressure regulation (187, 188) and possibly in angiogenesis. (189-191) These 
and other findings have led to the hypothesis that HO-1 has a role in pre-eclampsia. (142, 193) 
We are unable to find data on plasma HO-1 in either hypertension or pregnancy, although Bao et 
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al (199) imply a relationship with diabetes and hypertension. Plasma HO-1 may theoretically 
raise from the endothelium, (198) but although there is a growing body of tissue culture and 
animal model data on this molecule, (200, 201) at present we are unable to speculate further on 
its role in pregnancy induced hypertension. Nevertheless, it is clear that HO-1 is being viewed 
with increased interest, as it has been hypothesised that there is a protective role of HO-1 in 
pregnancy and that HO-1 may be a target for the treatment of preeclampsia. (202) The 
cardiovascular drugs, statins, stimulate HO-1 expression and inhibit sFlt-1 release in vivo and in 
vitro, thus, they have the potential to ameliorate early onset preeclampsia. This is being tested in 
the StAmP trial.  
Although limited by its cross-sectional design and relatively small sample size, the subject 
groups were matched with respect to age, and we therefore conclude that normal pregnancy is 
characterised by low angiogenin, low HO-1 and a high sFlt-1/VEGF ratio, but in hypertensive 
pregnancy, angiogenin and HO-1 levels remain similar to those in normal pregnancy.  Further 
studies, longitudinal in design and involving larger sample sizes are required to clearly establish 
a possible aetiological association between an imbalance in growth factor regulation and HO-1 
and the development of complications and adverse outcomes in hypertension in pregnancy. This 
may reflect differences in endothelial cell biology in the differing physiological and pathological 
states.  
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TABLE 3.3.1: LEVELS OF vWF, VEGF, sFlt-1, sFlt-1:VEGF RATIO, ANGIOGENIN 
AND HO-1 LEVELS BY GROUPS 
 
 
 
 
 
 
Non-pregnant 
controls  
(n=50) 
 
 
Normotensive 
Pregnant  
(n=38) 
 
Hypertensive  
Pregnant 
(n=38) 
 
P value 
Age (years) 30 (8) 29.5 (6) 33 (6) 0.113 
vWf (IU/dl) 115 (30) 156 (27)a 157 (32)a <0.001 
VEGF (ng/mL) 0.59 (0.24-1.35) 0.26 (0.1-1.67) 0.18 (0.1-0.68)a 0.013 
sFlt-1 (ng/mL) 13.5 (1.0-121) 17.5 (9.5-270) 12.5 (7.2 – 26.3) 0.195 
sFlt-1/VEGF ratio 23 (8-132) 135 (54-272)a 74 (21-147)a <0.001 
Angiogenin (ng/mL) 225 (134-331) 145 (91-230)a 195 (145-320)b 0.027 
Haem oxygenase-1 
(ng/mL) 
2.4 (1.6-4.0) 1.47 (0.8-2.4)a 1.6 (1.4-3.2) 0.026 
Data are presented as mean with (SD) or median with (IQR). Analyses by ANOVA or the 
Kruskal Wallis test as appropriate. Tukey’s post hoc test for inter-group differences – a: 
Significantly different from non-pregnant controls (p<0.05), b: Significantly different from 
normal pregnancy (p<0.05).  
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TABLE 3.3.2: CHANGES IN BLOOD PRESSURE AND PLASMA MARKERS IN 23 
HYPERTENSIVE PREGNANCIES 
 
 
 
 
 
 
Early pregnancy: 
14.9 (2.9) weeks 
 
 
Late pregnancy: 
30.1 (3.3) weeks 
 
P value 
SBP (mmHg)  133 (14) 133 (17) 0.943 
DBP (mmHg)  88 (10) 86 (10) 0.569 
vWf (IU/dl) 127 (46) 162 (29) 0.008 
VEGF (ng/mL) 0.11 (0.05-0.46) 0.21 (0.05-0.70) 0.022 
sFlt-1 (ng/mL) 11.0 (6.2-16.1) 12.0 (6.4-24.0) 0.601 
Angiogenin (ng/mL) 220 (125-370) 165 (125-260) 0.126 
Haem oxygenase-1 (ng/mL) 1.56 (0.8-3.0) 1.60 (1.4-3.2) 0.351 
Data are presented as mean with (SD) or median with (IQR). Analyses by paired t test or 
Wilcoxon’s test as appropriate.  
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Figure 3.3.1: Levels of Vascular Endothelial Growth Factor (VEGF), soluble Flt-1, VEGF: 
sFlt-1 ratio, angiogenin and Haem oxygenase-1 (HO-1) by groups 
 
(a) Vascular Endothelial Growth Factor 
VEGF by groups
HBP NBP HC
0
1
2
3
4
Study groups
VE
G
F 
le
v
el
s 
 
(p
g/
m
l)
 
(b) Soluble Flt-1 
sFlt-1 levels by groups
HBP NBP HC
0
100
200
300
400
500
Study Groups
sF
lt-
1 
le
v
el
s 
(n
g/
m
l)
 
  
100 
 
(c) VEGF: sFlt-1 ratios 
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(e) Haem oxygenase-1 
HO-1 levels by groups
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3.4 MMP-9/ TIMP-1 in hypertension in pregnancy 
Introduction 
A normally functioning extra cellular matrix is essential for successful trophoblast invasion. The 
matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) play a vital role and enable 
the restructuring of the extracellular matrix and hence tissue composition. This is important for 
processes including angiogenesis, vasculogenesis and normal endothelial function.  
The TIMP are a group of endogenous MMP inhibitors that can both modulate and inhibit MMP 
activity. It has been hypothesised that a balance between their respective activities determines the 
dynamics of the extra cellular matrix. Their levels are considered to reflect extra cellular matrix 
turnover. (203-205) 
We hypothesized that hypertension in pregnancy is characterised by abnormalities in the extra 
cellular matrix as indicated by altered levels of MMP-9 and TIMP-1 as well as MMP-9/ TIMP-1 
ratios. We tested our hypothesis on a cross-section of women attending our antenatal 
hypertension clinic. 
Methods 
Subjects 
The study compared markers of extra cellular matrix (MMP-9 and TIMP-1) in hypertensive 
pregnant women and in controls (normotensive pregnant women and matched non pregnant 
controls).  
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Collection of Blood Samples and Laboratory Methods 
Blood samples were collected from a large ante cubital vein using a 21-gauge needle directly 
into Vacutainer tubes (Becton Dickinson, UK) containing 7.2mg tri-potassium (K3) Ethylene 
Diamine Triacetic Acid (EDTA), 0.5mL 3.2% sodium citrate or Z serum clot activator. For 
enzyme-linked immunosorbent assay (ELISA) blood samples were centrifuged within 30 min 
from collection at 1,500g for 20 minutes at 4°C. The resultant supernatant (plasma/serum) was 
then collected and stored at -70°C until batch processing by ELISA to measure MMP-9 and 
TIMP-1  [R & D Systems, Europe, Oxon, UK]. All assays were performed according to the 
manufacturers’ guideline and locally developed protocols. The intra and inter-assay co-efficient 
of variation was <5% and <9% respectively for all assays. 
Power calculations and statistical analyses 
These have been described in previous chapters. 
Results  
We recruited 38 hypertensive pregnant women, 40 normotensive pregnant women and 50 non-
pregnant healthy women as controls.  
Both hypertensive pregnant women as well as normotensive pregnant women had raised MMP-9 
levels compared to non-pregnant healthy controls. TIMP-1 levels were relatively similar in the 
three groups. The MMP-9: TIMP-1 ratios were however significantly altered between the 
groups, with raised ratios in the hypertensive pregnant groups (p < 0.05). (Figure 3.4.1) 
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Discussion 
The role of the extra cellular matrix in the pathogenesis of hypertension in pregnancy and 
complications including preeclampsia has been examined previously. (116, 118, 126) 
The circulating levels of MMP-9 and TIMP-1 have been shown to be raised in hypertension. 
(206) This trend is noted in our current study, although the raised levels in hypertensive 
pregnancy are not statistically significant, perhaps related to small numbers of subjects. 
However, the altered ratio between MMP-9 and TIMP-1 suggests a possible abnormality in the 
extra cellular matrix turn over. The raised MMP-9/TIMP-1 ratio in both the pregnant groups and 
more so in the hypertensive pregnant group compared with the non-pregnant control group 
suggests enhanced metalloproteinase activity and extra cellular matrix breakdown. This finding 
is similar to that in the study by Palei et al, (126) who noted a higher net MMP-9 activity in their 
cohort with gestational hypertension. The suggestion of higher MMP-9 activity leading to 
accelerated cleaving of big endothelin-1 to yield medium endothelin-1, a more potent 
vasoconstrictor than endothelin-1 itself is worth consideration. 
Studies have shown that MMPs can activate vasoconstrictors (e.g. endothelin), inactivate 
vasodilators (e.g. calcitonin gene related peptide) and transactivate cell surface receptors 
responsible for vasoconstriction (e.g. epidermal growth factor receptor). (207) 
Study Limitations 
The limitations discussed previously remain so with this study. The study findings and the lack 
of significant differences in the levels of MMP-9 and TIMP-1 are different from those of a 
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previous study in our department. (206) It is difficult to explain this and relates probably to 
differences in the study cohort, maternal age, gestational age etc. 
Conclusions 
Our findings confirm significant alterations in matrix metalloproteinase activity in pregnancies, 
particularly those complicated with hypertension. Further studies involving larger sample sizes 
and longitudinal in design are required to clearly establish a possible aetiological association 
between abnormalities in extra cellular matrix breakdown and hypertension in pregnancy. 
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TABLE 3.4.1: LEVELS OF MMP-9, TIMP-1 and MMP-9: TIMP-1 RATIOS BY 
GROUPS 
 
Mean (SD) 
Hypertensive 
Pregnant 
(n=38) 
Normotensive 
Pregnant 
(n=41) 
Non-pregnant 
healthy 
controls (n=50) 
p-value 
Age (years) 32.61 (5.93) 29.32 (6.11) 30.46 (7.72) 0.0935 
Gestational Age 
(weeks) 
30.00 (3.07) 26.70 (3.40) NA 
< 0.0001 
Median (IQR) Parity 2 (0-5) 1 (0-6) 0 (0-4) < 0.0001 
Median (IQR)  
MMP-9  (pg/ml)  
530  
(100-6000)  
440  
(100-6000) 
335  
(100-6000) 
0.0748 
Median (IQR) 
TIMP-1 (pg/ml)  
2000 
(400-6000)  
2000 
(500-6000) 
1900 
(400-6000) 
0.3122 
MMP-9: TIMP-1 
ratio 
0.45 0.34 0.19 < 0.05 
(0.0414) 
Between group analyses by ANOVA with Tukey post hoc test and Kruskal Wallis test with 
Dunn’s post hoc test, as appropriate. 
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Figure 3.4.1: MMP-9, TIMP-1 and MMP-9: TIMP-1 ratios by groups 
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(c)  MMP-9: TIMP-1 ratios  
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3.5 Soluble Fas, soluble Fas-ligand in hypertension in pregnancy  
Introduction 
This study explores the role of apoptosis in hypertension in pregnancy and alterations in the 
levels of markers of apoptosis compared with healthy controls. 
Although abnormalities in placentation may be the primary pathology responsible for the 
development of pre-eclampsia and its effects, and a possible cause for this may be irregularities 
in the crucial relationship between Fas (a member of the tumour necrosis factor receptor 
superfamily [TNFRSF]) and its ligand (i.e. FasL), which in part regulate apoptosis, (208-210) on 
key endothelial cells. Fas (CD95, but also known as Apo-1 and TNFRSF6) is a 45-kDa type I 
membrane receptor containing an 80-amino acid intra-cellular ‘death’ domain in the 
intracytoplasmic tail. Engagement of membrane bound Fas by its ligand (CD95L, also known as 
TNFSF6), a 36-40 kDa type II membrane TNFSF member) triggers apoptosis by inducing the 
caspase series of enzymes. Current thought suggests apoptosis has a central role in the villous 
trophoblast turnover, as controlled apoptosis, mediated mainly through Fas-FasL signalling, and 
may be a defence mechanism against rejection of the foetal allograft by maternal immune 
system. (211) 
The Fas/FasL system may also be important in small-for-gestational age babies, although this is 
controversial. (97, 212, 213) Nevertheless, there is evidence of changes in Fas and FasL that 
imply a role in pre-eclampsia. (89, 97, 98) Furthermore, Fas and FasL may also be involved in 
the hypertension of pregnancy as Koenig and Chegini reported differential expression of Fas and 
FasL in foetal membranes, decidua and placentas from gestations with hypertension than in 
normal controls. (214) Matrix metalloproteinases are able to cleave FasL, leading to a soluble 
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form measurable in plasma, as reported in pre-eclampsia, pregnancy and in the syndrome of 
haemolysis, elevated liver enzymes, and low platelets. (98, 149, 215, 216) However, there are no 
reports of plasma Fas and FasL in the hypertension of pregnancy or any of the effects of parity. 
We hypothesised altered levels of Fas and FasL in the plasma of women whose pregnancy is 
complicated by hypertension compared with women with normotensive pregnancies and 
normotensive non-pregnant women that levels would change as pregnancy proceeds. We tested 
our hypotheses on a cross-sectional study of women attending a specialist antenatal hypertension 
clinic, a standard antenatal clinic, and in healthy non-pregnant women.  
Methods 
Twenty women were recruited early in their pregnancy (around week 14), and 29 later in their 
pregnancy, at approximately at week 28. Eighteen women were studied at both stages. A parallel 
group of 20 pregnant women with normal blood pressures were recruited at week 14, and another 
29 women were recruited at around week 28. The study was completed by the recruitment of 50 
women who were not pregnant.  
Collection of Blood Samples and Laboratory Methods 
Blood samples were collected using a 21-gauge needle directly into Vacutainer tubes (Becton 
Dickinson, UK) containing sodium citrate. Blood samples were centrifuged within 30 min from 
collection at 1,500g for 20 min at 4°C. The resultant supernatant plasma was collected and stored 
at -70°C until batch processing by ELISA for Fas and sFas ligand (R&D Systems, Abingdon, 
UK). Lower limited of detection were 100 pg/mL for sFas and 20 pg/mL for sFasL. The intra 
and inter-assay co-efficient of variation was <5% and <10%, respectively for all assays.  
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Power calculations and statistical analyses 
There are no reports of sFas or sFasL in the hypertension of pregnancy on which to base a power 
calculation. However, as other sample sizes in other sFas/sFasL cross sectional studies range 
from n=20 to n=30 per group, (149, 214-216) we recruited to this target for the pregnant groups, 
and to approximately twice as many non-pregnant women. Following a test of statistical 
normality, data were expressed as mean (standard deviation, SD) or median (inter-quartile range, 
IQR), as appropriate. Non-categorical data distributed normally were analysed by one way 
ANOVA, non-parametric data were analysed by Kruskal Wallis. Intergroup differences were 
sought by Tukey’s post hoc test. Correlations were sought by Spearman’s rank method. 
Categorical data (parity) were analysed by the chi-squared test, paired data (18 hypertensive 
women at week 20 and again at week 29) by paired t test or Wilcoxon’s test. A two-tailed p<0.05 
was considered as significant. 
Results  
Clinical, demographic and sFas/sFasL data of the subjects are presented in table 3.5.1. The 
subject groups and controls were matched for age but not parity, which increased from the non-
pregnant women (median no children), to the normotensive women (median one child), to the 
hypertensive women (median 2 children).  
There were no differences in sFas between the groups at either time point (early or late 
pregnancy). sFasL was lower, and the sFas/sFasL ratio was higher, in hypertensive pregnancy at 
both time points compared to both other groups. In the early stages of pregnancy (approximately 
week 14), sFasL was unrelated to parity (p=0.058). In the late stages of pregnancy 
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(approximately week 28), sFasL was also unrelated to parity (p=0.065).  (Table 3.5.1) (Figure 
3.5.1). 
sFas and sFasL were measured in 18 women both early and late in their pregnancy. There was no 
difference in levels of sFas at the two time points: 1550 (1200-1750) pg/mL at week 20 and 1550 
(1175-1825) pg/mL at week 29 (p=0.955). However, sFasL fell from 130 (85-213) pg/mL at 
week 20 to 125 (98-735) pg/mL at week 29 (p=0.028). The sFas/sFasL ratio also fell from 10.3 
(6.0-18.1) to 9.9 (4.1-14.1) (p=0.021). sFas, sFasL and their ratio failed to correlate significantly 
with gestational age, maternal age, SBP or DBP at either time point in the pregnant women, or in 
the pregnant women. sFas correlated with sFasL in all groups at all time points (r 0.45 - 0.74, 
p=0.002 - <0.001) except in the hypertensive women early in their pregnancy (r=0.39, p=0.092). 
(Table 3.5.2) 
Discussion 
We examined the role of sFas and sFasL in normal pregnancy and in the hypertension of 
pregnancy, focussing on both early and late stages. We found no difference in sFas, sFasL or 
their ratio in normal pregnancy compared with no pregnancy, and no change over the duration of 
the pregnancy, thus failing to confirm others who found low sFas in similar numbers of women 
with a normal pregnancy. (216) Harirah et al found serum levels of sFas, but not sFasL, to be 
significantly higher in women with the syndrome of haemolysis, elevated liver enzymes, and low 
platelets (HELLP) syndrome than healthy gravidas. (149) Although Koenig and Chegini 
observed greater expression of Fas and FasL in amnion and decidual tissue from hypertensive 
pregnancy gestations than in normal control pregnancies, they did not report plasma levels. (214) 
We complement their data by reporting low sFasL and high sFas/sFasL ratio in hypertensive 
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pregnancy compared to non-pregnancy and normal pregnancy at both early and late stages of 
pregnancy. However, Kuntz et al (98) also found higher sFasL in pre-eclamptic pregnancy 
compared with control gestations but no difference in sFas. Thus, although comparison between 
research reports may be flawed, we and Kuntz et al both found measurement of sFas to be 
unhelpful. Our finding of low sFasL in hypertensive pregnancy is the reverse of their finding of 
high levels in pre-eclamptic pregnancy.  
The relationship between Fas and FasL within the pregnant uterus may be important in 
minimising the maternal allogeneic response (208-211, 217-219), and failure of this system may 
be important in pre-eclampsia and other conditions. (89, 220, 221) This has led to interest in 
potential roles for the measurement of these molecules in maternal blood as indicators of actual 
or potential complication such as intra-uterine growth retardation. (97, 98, 149, 212, 213, 216)  
Although a recent report failed to find a role for sFas and sFasL in intra-uterine growth 
retardation, (213) these molecules may be important in the neonatal period. (222) Although 
limited by its cross-sectional design and relatively small sample size (which is comparable to, or 
exceeds, similar studies, (97, 98, 149, 213, 214, 216, 222) the subject groups were matched with 
respect to age. An additional caveat is the marked difference in parity.  
We therefore conclude that in normal pregnancy there is no change in sFas or sFasL. However, 
we found that sFas is low in hypertensive pregnancy, although this may be an effect of the 
increased parity in this group. Although sFasL and the sFas/sFasL ratio fell in 18 hypertensive 
women between weeks 20 and 29, this ‘mathematical’ decrease of 4% is unlikely to have clinical 
value. Further studies, longitudinal in design and involving larger sample sizes are required to 
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clearly establish a possible aetiological association between an imbalance in sFas and sFasL and 
the development of complications and adverse outcomes in hypertension in pregnancy.  
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TABLE 3.5.1: SERUM FAS/FAS LIGAND DATA BY GROUPS 
 
 
 
 
 
Non-
preg 
women 
(n=50) 
 
 
Early 
normotensive 
pregnancy 
(n=20) 
 
 
Early 
hypertensive 
pregnancy 
(n=20) 
 
P 
value 
(early)a 
 
Late 
normotensive 
pregnancy 
(n=29) 
 
Late 
hypertensive 
pregnancy 
(n=29) 
 
P value  
(late)b 
Age 
(years) 
 
30.5 
(7.7) 
28.9 (6.3) 33.0 (3.2) 0.143 29.5 (6.1) 32.5 (5.8) 0.232 
Gestation 
age 
(weeks) 
- 13.7 (2.5) 14.8 (3.1) 0.224 27.8 (3.5) 29.0 (2.6) 0.150 
sFas 
(pg/mL) 
1400 
(1175-
1850) 
1300 
(985-1700) 
1450 
(1200-1700) 
0.350 1700 
(110-2200) 
1500 
(1200-1850) 
0.702 
 
sFas 
Ligand 
(pg/mL) 
985 
(198-
2000) 
730 
(113-1650) 
157** 
(98-438) 
0.005 1050  
(148-1925) 
180** 
(100-1525) 
0.038 
sFas/sFas 
Ligand 
ratio 
1.9  
(0.9-6.5) 
1.95  
(1.1-8.5) 
8.45**  
(3.0 – 16.8) 
0.005 2.0  
(1.4-9.7) 
9.8**  
(1.6-13.4) 
0.007 
Data presented as mean (SD) or median (IQR). P values by ANOVA or the Kruskal-Wallis test. aBetween 
non pregnant women, early normotensive pregnancy and early hypertensive pregnancy. bBetween non 
pregnant women, late normotensive pregnancy and late hypertensive pregnancy. Sub-analyses by Tukey’s 
test: **Significantly different (p<0.05) in hypertensive pregnancy than in the other 2 groups.  
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Figure 3.5.1: soluble Fas, soluble Fas ligand and sFas: sFasL ratios by groups 
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(c) sFas: sFasL ratios 
sFas/sFasL ratios by groups
HBP NBP HC
0
10
20
30
40
Study groups
sF
as
/s
Fa
sL
 
ra
tio
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
118 
 
3.6 Pregnancy Outcomes and correlation between biomarkers 
 
Introduction  
The Vascular Biology of Pregnancy explored the role of various processes occurring in the 
maternal vasculature and their role in the pathogenesis of hypertensive disorders of pregnancy 
and its effects on pregnancy. 
This chapter aims at examining the differences in the pregnancy outcomes observed in the two 
pregnant groups and seeks to establish correlations between the biomarkers studied. 
Methods 
Subjects 
The study compared pregnancy outcomes in hypertensive pregnant women and in the 
normotensive pregnant controls. 
The inclusion and exclusion criteria of study subjects have been discussed as before, as also the 
collection of blood samples and various laboratory methods. 
Results  
We recruited 40 hypertensive pregnant women, 60 normotensive pregnant women and 50 non-
pregnant healthy women as controls. The gestational age and parity were higher in the 
hypertensive pregnant women group. (Table 3.6.1) 
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We report the pregnancy outcome data on 34 hypertensive and 38 normotensive pregnant 
women. As expected, both systolic and diastolic blood pressures were significantly higher in the 
hypertensive pregnant group (p<0.001).  
Women in the hypertensive group were older in age (mean age 33 years) compared with those in 
the normotensive group (mean age 27 years) and delivered earlier (median gestational age 38.6 
weeks, compared with 39.8 weeks in the normotensive group). Of the 34 hypertensive women, 
16 delivered by Caesarean section compared with only 10 normotensive women who required a 
Caesarean section. The earlier delivery in the hypertensive group could perhaps be related to 
elective Caesarean sections in view of potential risks anticipated with the progression of 
gestation.  
Although the babies born to the hypertensive group were smaller than those born to the 
normotensive group, there was no significant difference in length, weight, head circumference 
and APGAR scores between the babies in the two groups. No significant morphological 
abnormalities were noted in the babies born to both groups of women. This is easily explained by 
the relatively small numbers of subjects in both groups and lack of power to demonstrate a 
significant difference in outcomes. 
We estimated the correlations between the biological markers [circulating endothelial cells 
(CECs), circulating progenitor cells (CPCs), von Willebrand factor (vWf), vascular endothelial 
growth factor (VEGF), soluble fms like tyrosine kinase -1 (sFlt-1), serum fas (sFas), serum fas 
ligand (sFasL), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 
(TIMP-1), and haem oxygenase-1 (HO-1). 
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A negative correlation was noted between gestational age at delivery and systolic as well as 
diastolic blood pressures (Spearman correlations -0.312, p<0.001). Similarly, birth length, 
weight and head circumference of the babies born also negatively correlated with the systolic as 
well as diastolic blood pressures of the mothers (systolic blood pressures: Pearman correlations, -
0.501, -0.379 and -0.435 respectively, p<0.05; diastolic blood pressures: Pearman correlations, -
0.401, -0.312 and -0.324 respectively, p<0.05). Amongst the biomarkers, circulating endothelial 
cells correlated positively with both systolic and diastolic blood pressures (Spearman correlation 
rho 0.279 and 0.309, p<0.001 respectively). 
An analysis of correlations between the biomarkers revealed a few positive correlations, which 
are summarised in table 3.6.2. It is noteworthy that CEC and CPC levels both correlate well with 
vWF levels. In addition, CEC levels correlate positively with sFlt1 and MMP 9 levels. vWF and 
VEGF levels correlate well with sFlt 1. Further, VEGF levels also correlate with the markers of 
apoptosis and HO-1. 
We have demonstrated a positive correlation between angiogenin and HO-1 levels. HO-1, in turn 
correlates well with VEGF, sFlt1 as well as sFas and sFasL levels. 
Discussion 
This study is probably one of the first to explore a range of biomarkers and their association with 
clinically relevant pregnancy outcomes. 
The findings confirm a relationship between raised blood pressures in pregnant women and 
adverse outcomes, including relatively low birth weight of the new born babies.  
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Also notable is the association between the different processes occurring in the maternal 
vasculature, including endothelial dysfunction and its repair, new blood vessel formation 
(angiogenesis), the break down processes (apoptosis), and the extracellular matrix and the haem 
oxygenase systems. 
The correlations described above generate many a question and raise one’s inquisitiveness to 
further explore the maternal vasculature with a view to evolving novel, but safe therapies 
targeting these specific pathways so as to prevent the development of hypertensive disorders in 
pregnancy and hence preventing any adverse outcomes. It may be noted that the study design 
does not allow for a detailed exploration of the underlying mechanisms and causes for the 
observed correlations between the biomarkers and the above theories are merely speculative. 
Study Limitations 
The limitations of the study have been extensively discussed in the individual data chapters and 
pertain mainly to the cross-sectional design and relatively small numbers of subjects. 
We were unable to demonstrate clear alterations in the biomarkers with progression of gestation, 
particularly in the normotensive pregnant group due to very small numbers being followed up in 
the hospital clinics, compared with the hypertensive pregnant women, who were followed up 
more closely both before and after delivery. 
Conclusions 
Our findings confirm the association between hypertension in pregnancy and adverse outcomes 
as well as the complex interplay and relationship between the dynamic processes that occur in 
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the maternal vasculature. Whether these are merely associated with hypertension or whether they 
have a cause-effect relationship needs to be explored in larger clinical trials. 
Further, large longitudinal studies would need to be conducted to demonstrate a significant 
difference in clinical outcomes in pregnant women affected by hypertensive disorders compared 
with those whose blood pressures remain normal throughout their pregnancies. 
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TABLE 3.6.1: BASELINE CHARACTERISTICS OF THE STUDY GROUPS 
 
Mean (SD) 
Hypertensive 
Pregnant 
(n=34) 
Normotensive 
Pregnant 
(n=38) 
p-value 
Age (years) 32.78 (4.82) 28.11 (5.9) 0.007 
Gestational Age 
(weeks) 
37.85 (3.94) 39.48 (1.46) 
0.05 
Median (IQR) Parity 2 (0-5) 1 (0-7) < 0.0001 
SBP (mm Hg)  133(17) 112 (9) < 0.0001 
DBP (mm Hg)  87 (11) 66 (6) < 0.0001 
Birth weight (kg) 3.03  (0.81) 3.29 (0.50) 0.180 
Birth length (m) 0.50 (0.06) 0.51 (0.03) 0.181 
Ponderal Index  23.99 (3.83) 24.25 (2.97) 0.794 
Head Circumference 
(m) 
0.33 (0.04) 0.34 (0.01) 0.214 
APGAR1 9 (0-9) 9 (6-9) 0.455 
APGAR2 9 (0-10) 9 (8-10) 0.275 
Between group analyses by ANOVA with Tukey post hoc test and Kruskal Wallis test with 
Dunn’s post hoc test, as appropriate 
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TABLE 3.6.2: CORRELATIONS BETWEEN THE BIOMARKERS 
 
   CEC CPC vWF VEGF sFlt1 Angiogenin sFas sFasL MMP9 TIMP1 HO1 
Spearman's rho CEC Correlation 
Coefficient 1.000 -.091 
.402*
*
 
.024 .204* -.092 .094 .077 .277** .014 -.011 
Sig. (2-tailed) . .337 .000 .785 .021 .303 .292 .388 .002 .872 .898 
N 128 112 128 128 128 128 128 128 128 128 128 
CPC Correlation 
Coefficient -.091 1.000 .230
*
 -.083 .044 .071 -.114 -.120 .173 .115 .015 
Sig. (2-tailed) .337 . .015 .384 .644 .458 .230 .208 .068 .226 .876 
N 112 112 112 112 112 112 112 112 112 112 112 
vWF Correlation 
Coefficient 
.402*
*
 
.230* 1.000 .000 .208* .107 -.068 .034 .408** .159 -.086 
Sig. (2-tailed) .000 .015 . .994 .019 .229 .445 .701 .000 .074 .336 
N 128 112 128 128 128 128 128 128 128 128 128 
VEGF Correlation 
Coefficient .024 -.083 .000 1.000 
.531*
*
 
.051 .485
*
*
 
.790** .018 .060 .182* 
Sig. (2-tailed) .785 .384 .994 . .000 .564 .000 .000 .841 .499 .039 
N 128 112 128 129 129 129 129 129 129 129 129 
sFlt1 Correlation 
Coefficient .204
*
 .044 .208* .531** 1.000 .011 .330
*
*
 
.538** .104 .094 .180* 
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 CEC CPC vWF VEGF sFlt1 Angiogenin sFas sFasL MMP9 TIMP1 HO1 
Sig. (2-tailed) .021 .644 .019 .000 . .902 .000 .000 .240 .292 .041 
N 128 112 128 129 129 129 129 129 129 129 129 
Angiogenin Correlation 
Coefficient -.092 .071 .107 .051 .011 1.000 .038 .027 -.142 -.161 
.257*
*
 
Sig. (2-tailed) .303 .458 .229 .564 .902 . .667 .764 .108 .069 .003 
N 128 112 128 129 129 129 129 129 129 129 129 
sFas Correlation 
Coefficient .094 -.114 -.068 .485
**
 
.330*
*
 
.038 1.000 .445** -.118 .025 .324
*
*
 
Sig. (2-tailed) .292 .230 .445 .000 .000 .667 . .000 .182 .777 .000 
N 128 112 128 129 129 129 129 129 129 129 129 
sFasL Correlation 
Coefficient .077 -.120 .034 .790
**
 
.538*
*
 
.027 .445
*
*
 
1.000 .051 .105 .156 
Sig. (2-tailed) .388 .208 .701 .000 .000 .764 .000 . .563 .236 .077 
N 128 112 128 129 129 129 129 129 129 129 129 
MMP9 Correlation 
Coefficient 
.277*
*
 
.173 .408
*
*
 
.018 .104 -.142 -.118 .051 1.000 .576** .051 
Sig. (2-tailed) .002 .068 .000 .841 .240 .108 .182 .563 . .000 .565 
N 128 112 128 129 129 129 129 129 129 129 129 
TIMP1 Correlation 
Coefficient .014 .115 .159 .060 .094 -.161 .025 .105 .576
**
 1.000 .118 
Sig. (2-tailed) .872 .226 .074 .499 .292 .069 .777 .236 .000 . .183 
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 CEC CPC vWF VEGF sFlt1 Angiogenin sFas sFasL MMP9 TIMP1 HO1 
N 128 112 128 129 129 129 129 129 129 129 129 
HO1 Correlation 
Coefficient -.011 .015 -.086 .182
*
 .180* .257** .324
*
*
 
.156 .051 .118 1.000 
Sig. (2-tailed) .898 .876 .336 .039 .041 .003 .000 .077 .565 .183 . 
N 128 112 128 129 129 129 129 129 129 129 129 
**. Correlation is significant at the 0.01 level (2-
tailed). 
           
*. Correlation is significant at the 0.05 level (2-tailed).            
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Section 4: Summary 
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4.1 Summary of Findings 
 
 
The results of the Vascular Biology of Pregnancy project can be summarised as follows: 
• Hypertension in pregnancy is associated with significant alterations in the internal milieu 
of the maternal vasculature. 
• It is characterised by endothelial dysfunction, with a significant increase in circulating 
endothelial cells as well as von Willebrand factor compared with pregnant women with 
normal blood pressures and non-pregnant healthy controls. 
• An active process of endothelial repair occurs in these women, suggested by a reduced 
number of circulating progenitor cells, possibly related to a consumptive state, compared 
with normotensive pregnant controls. 
• Vascular endothelial growth factor levels are lower, further raising the possibility of their 
recruitment in the endothelial reparative processes. 
• Our findings also suggest an increase in angiogenesis, evidenced by higher angiogenin 
levels; alterations in the matrix metalloproteinases (increase in MMP-9 levels);  
• However, we were unable to demonstrate significant changes in the markers of apoptosis.  
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4.2 Conclusions 
 
The ‘Vascular Biology of Pregnancy’ is a comprehensive study of the maternal vasculature in 
pregnancies complicated by hypertension, both pre-existing as well as pregnancy-induced. The 
study has revealed significant associations between endothelial dysfunction and abnormalities in 
angiogenesis and apoptosis as well as the haem oxygenase system and the extra-cellular matrix 
in hypertensive pregnancies and is perhaps the first of its kind to demonstrate correlations 
between the different biomarkers that characterise these processes. 
 
Progression of hypertensive pregnancies to the development of preeclampsia and its clinical 
manifestations are hypothesised to be associated with two potentially interrelated events: a 
relative placental hypoxia/ischemia linked to diffuse maternal endothelial cell activation. In a 
majority of women, the development of preeclampsia occurs at or close to term when prompt 
delivery of the foetus is associated with good maternal and foetal outcome. (223) 
 
However, a proportion of women develop more severe early onset disease (<34 weeks gestation) 
associated with increased foetal and maternal morbidity and mortality. (224) It is, however, 
unclear whether these two phenotypes (mild late onset and severe early onset) represent two 
differing pathophysiologies (placental vs. maternal). (225) Changes in the maternal circulation, 
including increases in plasma volume, cardiac output and heart rate combined with decreasing 
blood pressure during pregnancy, together constitute the largest cardiovascular challenge that the 
maternal system ever faces (226). Further, pre-existing altered vascular function/reactivity 
resulting from a systemic response to inflammation and oxidative/nitrative stress in the mother 
arising from an inadequately perfused placenta is the underlying cause of preeclampsia. (225) 
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Significant changes occur in the maternal cardiovascular system throughout gestation beginning 
soon after conception with the objective of increasing blood flow and nutrient delivery to the 
foetal-placental unit. Blood volume increases from 6 to 8 weeks gestation onwards by 45% to 
reach approximately 5 litres at 32-weeks’ gestation. (227) The increase in red blood cell mass 
(20–30%) leads to physiologic haemodilution, reduces blood viscosity, thus potentially 
protecting from the predisposition for thromboembolic events in pregnancy (228) and permitting 
placental perfusion. Cardiac output increases 30–50% in pregnancy. (229) Normal pregnancy is 
associated with increased endothelium-mediated relaxation, blunted response to vasoconstrictors 
and increased flow-mediated dilation. (230) Blood flow to the uterus increases tenfold in 
gestation (from 2% to 17% of cardiac output) reaching 500–800 mL/min at term, half of which 
goes to the placental intervillous space to sustain the developing placenta and foetus. (231). 
Animal model studies have shown that reductions in uteroplacental blood flow can lead to a 
hypertensive state that closely resembles preeclampsia. (232) 
 
Arteries in the placental bed arteries are modified to reach a high-flow, low-resistance state to 
support this increased blood flow. This is achieved by extra villous trophoblast-mediated 
remodeling of spiral arteries with replacement of endothelium by trophoblasts. (233) Placental 
bed biopsies from women with preeclampsia have shown that physiological changes in the 
arteries found in normal pregnancies are restricted, being limited to decidual portions of the 
vessels or absent altogether. (234, 235) The mean external diameters of the spiral arteries in 
women with preeclampsia are less than half of similar vessels from uncomplicated pregnancies. 
The decreased diameter results in reduced placental perfusion.  
 
  
131 
 
Endothelial dysfunction appears to be the key and central pathological process related to various 
disease processes, including hypertension and cardiovascular diseases such as stroke and 
myocardial infarction. Some of the currently available drug therapies are hypothesised to 
influence and improve endothelial function and perhaps help prevent further events. However 
these therapies may be unsafe for use in women of child bearing age and during pregnancy. The 
other abnormalities described probably have more than a mere associative relationship to the 
disease processes. 
 
Although predominantly cross-sectional, it offers insight into the change in levels of the 
biomarkers with progression of gestation. Some of the findings are consistent with those from 
previous studies, whereas others have revealed a reverse trend, probably related to the 
characteristics of the study groups and notably the absence of pre-eclampsia/ eclampsia. 
Understandably, the numbers involved were small to explore for any clinical relevance of the 
difference in the biomarkers in the study groups.  
 
Hence we can conclude that abnormalities in the maternal vasculature as well as those affecting 
placentation and complex interactions between these two processes are related to hypertensive 
disorders in pregnancy and the resultant complications.  
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4.3 Suggestions for future studies 
 
The findings from our study provide insight into the pathophysiology of the changes in the 
vascular tree of pregnant women with hypertension.  
 
However, they also raise important questions that can perhaps be answered only by large multi-
centre prospective trials involving hundreds or thousands of patients to look further at the role of 
these pathological processes in the development of clinically significant adverse outcomes in the 
mother and the foetus.  
 
Further studies could aim at exploring the role and influence of the above biomarkers on clinical 
parameters including placental size, birth weight of the foetus, development of preeclampsia and 
eclampsia.  
 
Also of relevance would be large randomised trials to assess the influence of drugs (currently 
used to treat hypertensive disorders in pregnancy) on these pathological processes and whether 
they can cause regression of the underlying abnormalities and improve clinical outcomes. This 
would mean a multi-factorial prospective randomised trial comparing outcomes in pregnant 
women treated with currently available anti-hypertensive medications deemed safe for use 
during pregnancy.  
 
Another important question that needs to be addressed from future studies is to look for 
persistence in the described changes after delivery and following their trends in future 
pregnancies, perhaps even before conception, and whether they precede the clinical rise in blood 
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pressure., this would also be relevant with respect to any predisposition to the development of 
hypertension and cardiovascular disease in later life in the mother.  
 
Of particular note, this would also help determine whether periodic review and monitoring as 
well as continued treatment (if relevant) will prevent or delay the onset of cardiovascular disease 
in later life. However, monitoring with biomarkers would perhaps require evolving novel (cost-
effective) methods of testing that are easily reproducible, reliable and validated. 
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vii. Appendix 
 
Appendix 1 
 
Definition of Hypertension in pregnancy 
Hypertensive disorders are classified into 4 categories according to the Working Group Report 
on Hypertension in Pregnancy.(1) They are chronic hypertension, preeclampsia-eclampsia, 
preeclampsia superimposed upon chronic hypertension and gestational hypertension. 
 
Chronic Hypertension 
 
Chronic hypertension is defined as hypertension (blood pressure ≥140 mm Hg systolic and/ or 
≥90 mm Hg diastolic) that is present and observable before pregnancy or diagnosed before the 
20th week of gestation. Hypertension diagnosed for the first time during pregnancy and that does 
not resolve postpartum is also classified as chronic hypertension.(1) 
 
Preeclampsia-eclampsia 
 
Preeclampsia-eclampsia is a pregnancy-specific syndrome that usually occurs after 20 weeks’ 
gestation, or earlier in trophoblastic diseases (hydatidiform mole or hydrops). The increased 
blood pressure is accompanied by proteinuria in this syndrome.(1) 
 
Preeclampsia 
 
Preeclampsia is a syndrome characterized by hypertension, proteinuria and symptoms of 
headache, visual changes, epigastric or right upper quadrant pain and dyspnea. It may be mild or 
  
135 
 
severe, depending on the degree of hypertension, proteinuria and other organ system 
involvement. (7) 
 
Eclampsia 
 
Eclampsia is defined as the occurrence in a woman with preeclampsia of seizures that cannot be 
attributed to other causes. (1) 
 
Gestational Hypertension 
 
Gestational hypertension or pregnancy induced hypertension (PIH) is defined as a blood pressure 
>140 mm Hg systolic and/ or >90 mm Hg diastolic in a woman who was normotensive before 20 
weeks’ gestation. These recordings are on at least two occasions 6 hours apart, with the BP 
recordings used to establish the diagnosis no more than 7 days apart. (151)Severe gestational 
hypertension is a condition of sustained elevation in systolic blood pressure of >160 mm Hg and/ 
or in diastolic blood pressure of >110 mm Hg for 6 hours.  
Other clinical symptoms suggestive of this condition include headache, blurred vision, 
abdominal pain or abnormal lab tests, including low platelet counts and abnormal liver function 
tests. (1) 
 
Preeclampsia superimposed on chronic hypertension 
 
Preeclampsia may occur in women with chronic hypertension, with a much worse prognosis than 
with either condition alone. 
Possible findings in superimposed preeclampsia include 
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• New onset proteinuria (≥0.3g/ 24 hours) in women with hypertension and no proteinuria 
in early pregnancy (<20 weeks’ gestation). 
• Sudden increase in proteinuria 
• Sudden increase in blood pressure in a woman with previously well controlled 
hypertension 
• Thrombocytopenia (<100,000 platelets/mm3) 
Abnormal elevation in liver enzymes (alanine aminotransferase or aspartate aminotransferase)(1) 
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9. V J Karthikeyan, F Ali, S F Jewels, R E Ferner, S Baghdadi, & D G Beevers. 
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in 
pregnancy: a cause for concern (oral presentation).  
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x. Standard Operating Procedures 
1. von Willebrand factor 
Synopsis: 
This is the standard ELISA for the measurement of von Willebrand factor (vWf) using 
commercial antisera from Danish company Dako. The following method is for two plate’s worth 
of samples (about 80), taking about half a day. 
Brief Method: 
1. Coat microtitre plate with 100 µl of a dilution of primary antisera (35 µl in 20ml coating 
buffer) at room temperature (RT) for >60 minutes or overnight in the fridge. 
2. Wash 3x, add 100 µl 1/40 serum or plasma in pbs/tween, or neat tissue culture fluid, incubate 
for >60 minutes at RT. 
3. Wash 3x, add 100 µl peroxidase-labelled conjugate (35 µl in 20ml PBS) for >45 minutes at 
RT. 
4. Wash and add 100 µl substrate (OPD, hydrogen peroxide, citrate buffer). The colour 
develops almost immediately. 
5. Stop with 100 µl acid. Read at 492 nm. 
Expected values in citrated normal plasma in the region of 100 + 30 IU/dL stable atherosclerosis 
typically 130 + 35 IU/dL, acute coronary syndromes often 150 + 40. Data are generally of 
normal distribution.(236)      
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2. Vascular Endothelial Growth Factor (VEGF) 
Synopsis: 
The Vascular endothelial growth factor (VEGF) ELISA uses commercial antibody and requires 
about 4-6 hours to complete. 
 Brief Method: 
1. Coat microtitre plate with 112 µl of primary antisera l in 20 ml PBS buffer for 2 plates 
overnight in the fridge. 
2. Wash, block with 100 µl /well of 5% Marvel (1g in 20mls PBS-T for 2 plates) for 1 hour 
at RT. 
3. Wash and add 100 µl of neat plasma, or neat tissue culture fluid, and recombinant 
standards for 2 hours at RT. Standards are double diluted down the plate. Use fresh tips 
for each sample. 
4. Wash and add 112 µl of biotinylated anti-human VEGF antibody in 20 ml PBS tween for 
90 minutes at RT. 
5. Wash and add Streptavidin (100µl/well) for 45 minutes at RT. 
6. Wash and add 100 µl substrate (Solutions A and B) .Blue colour develops well within 20 
to 30 minutes 
7. Stop with 50 µl/well acid. Colour goes yellow. Read at 450 nm.  
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Expected values: 
Data usually not normally distributed. Controls generally have median values of about 30-50 
pg/ml [but inter-quartile range (IQR) may be over 200pg/ml]. Patients’ median values generally 
100 to > 200 pg/ml. (186, 237). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
144 
 
3. Vascular Endothelial Growth Factor Receptor (sFlt-1) 
Synopsis: 
The soluble form of Flt-1 (sFlt-1) ELISA measures free, as opposed to complexed sFlt-1 and will 
require about 10 hours to complete. 
 Brief Method: 
1. Coat microtitre plate with 100µl of primary antisera (40µl of 40µg/ml in 10ml coating 
buffer for 1 plate) overnight in the fridge. 
2. Wash and block with 200µl /well of 5% Marvel (2.5g in 50mls PBS-T for 2 plates) for 2 
hours. 
3. Wash and add rhVEGF to saturate the plate. Incubate for 2 hours at RT. 
4. Wash and add 100µl of neat plasma, or neat tissue culture fluid, and recombinant 
standards for 2 hours at RT 
5. Wash and add 100µl of 500ng/ml of biotinylated goat anti-human Flt-1 antibody (100µl 
of 5µg/ml in 10ml PBS) for 2 hours at RT. 
6. Wash and add extravidin peroxidase (100µl/well) for 45 minutes at RT. 
7. Wash and add 100µl substrate (OPD, hydrogen peroxide, citrate buffer) for 45minutes at 
RT. 
8. Stop with 50µl/well acid. Read at 492 nm 
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Expected values: 
The values are typically not normally distributed data. Median plasma concentration 10-30ng/ml 
with no changes or even lower levels in patients with vascular disease has been reported.(238, 
239). 
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4. Angiogenin 
Brief Method: 
1. Coat microtitre plate with 100µl of primary antisera/well at room temperature (RT) for 90 
minutes or at 4oC overnight. 
2. Wash and add serum/plasma and recombinant standards diluted in PBS/tween for 90 
minutes at RT. 
3. Wash and add 100µl of biotinylated anti-human angiogenin antibody (one vial for 10ml 
PBS-T) to each well for 90 minutes at RT. 
4. Wash and add 100ul/well of streptavidin-HRP (50ul strep-HRP in 10mls of PBS-T for 1 
plate) and incubate for at least 20 minutes at RT (avoid direct light). 
5. Wash and add 100µl WARM substrate solution (5mls A + 5mls B for 1 plate). Colour 
will develop in less than 5 minutes. 
6. Stop with 50µl/well acid. Read at 450 nm 
Expected values: 
Data usually not normally distributed. Controls generally have median values of about 5mcg/ml. 
Patients’ median values generally lower. 
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5. Soluble Fas  
Brief Method: 
1. Coat microtitre plate with 100µl of primary antisera (56µl of reconstituted primary Ab in 
10ml PBS for 1 plate) room temperature (working concentration 1µg/ml). 
2. Wash, block with 200µl /well of 5% Marvel (2.5g in 50mls PBS-T for 2 plates) for 1 
hours at RT. 
3. Wash and add 100µL serum (or EDTA plasma) diluted to 1 in 5 (by adding 20µL of 
sample to 80µL PBS-T) and recombinant standards for 2 hours at RT.  
4. Wash with PBS-T, add 100µl 56µl of reconstituted secondary Ab in 10ml PBS-T for 2 
hours at RT (working concentration 50ng/ml). 
5. Wash and add 100ul/well of streptavidin-HRP (50ul strep-HRP in 10mls of PBS-T for 1 
plate) and incubate for 20 minutes at RT (avoid direct light). 
6. Wash and add 100µl substrate solution 5 mls Colour regent A + 5 mls B for 1 plate. 
Colour will develop in less than 5 minutes. 
7. Stop with 50µl/well acid. Read at 450 nm. 
Expected values: 
Data are usually not normally distributed. Controls generally have median values of about 
5mcg/ml. Patients’ median values are generally lower. 
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6. Soluble Fas ligand  
Brief Method: 
1. Coat microtitre plate with 100µl of primary antisera (56µl of reconstituted primary Ab in 
10ml PBS for 1 plate) room temperature (working concentration 2µg/ml). 
2. Wash, block with 200µl /well of 5% Marvel (2.5g in 50mls PBS-T for 2 plates) for 1 
hour at RT. 
3. Wash and add 100µl serum and 100 µl recombinant standards for 2 hours at RT.  
4. Wash with PBS-T and add 56µl of reconstituted secondary Ab in 10ml PBS-T, then 
incubate for 2 hours at RT (working concentration 50ng/ml). 
5. Wash and add 100ul/well of streptavidin-HRP (50ul strep-HRP in 10mls of PBS-T for 1 
plate) and incubate for 20 minutes at RT (avoid direct light). 
6. Wash and add 100µl substrate solution 5 mls Colour regent A + 5 mls B for 1 plate. 
Colour will develop in less than 5 minutes. 
7. Stop with 75µl/well acid. Read at 450 nm. 
Expected values: 
Data usually not normally distributed. Controls generally have median values of about 5mcg/ml. 
Patients’ median values generally lower. 
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7. Matrix Metalloproteinase -9 
Synopsis: 
This is the standard ELISA for the measurement of Matrix Metalloproteinase-9 (MMP-9) using 
Duoset development kit from R & D Systems Europe. The following method is for two plate’s 
worth of samples (about 70), taking about a day. 
 Brief Method: 
1. Coat microtitre plate with 100 µl of a dilution of primary antisera (112 µl in 20ml coating 
buffer) overnight in the fridge. 
2. Block with Marvel (1.25g in 25mls PBS-Tween). 
3. Wash and add 100 µl  1/100 plasma, or neat tissue culture fluid, along with the standards for 
two hours at RT. 
4. Wash and add 100 µl biotinylated conjugate (112 µl in 20ml PBS-Tween) for 2 hrs at RT. 
5. Wash and add 100 µl substrate (Streptavidin - 100 µl in 20mls PBS-Tween) for 20 minutes in 
the dark. 
6. Wash four times and add 100 µl colour reagent (A&B, 5mls each). 
7. Stop with 100 µl acid. Read at 450 nm. 
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8. Tissue Inhibitor of Metalloproteinase-1 
Synopsis: 
This is the standard ELISA for the measurement of Tissue Inhibitor of Metalloproteinase-1 
(TIMP-1) using commercial antisera from R & D Systems Europe. The following method is for 
TWO plate’s worth of samples (about 40), taking about a day. 
 Brief Method: 
1. Coat microtitre plate with 100 µl of a dilution of primary antisera (112 µl in 20ml coating 
buffer) overnight in the fridge. 
2. Block with Marvel (0.4g in 10mls PBS-Tween). 
3. Wash and add 100 µl  1/00 plasma, or neat tissue culture fluid, for two hours at RT. 
4. Wash and add 100 µl biotinylated conjugate (112µl in20 mls PBS-Tween) for 2 hrs at RT. 
5. Wash and add 100 µl substrate (Streptavidin - 100 µl in 20mls PBS-Tween) for 20 minutes in 
the dark. 
6. Wash four times and add 100 µl colour reagent (A&B, 5mls each). 
7. Stop with 100 µl acid. Read at 450 nm. 
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9. Haem oxygenase-1 
Synopsis: 
This is the standard ELISA for the measurement of Haem oxygenase-1 (HO-1) using commercial 
antisera from Stressgen.  
Brief Method: 
Bring to room temperature: Anti-HO-1 Immunoassay Plate, 10X 
1. Wash Buffer, Sample Diluent, Anti-Human HO-1 Diluent, Anti-Rabbit IgG:HRP Conjugate 
Diluent, TMB Substrate and Acid Stop Solution. 
2. Prepare Recombinant HO-1 Standard and samples in Sample 
Diluent: 
3. Add 100µL prepared standards and samples in duplicate to wells of Anti-HO-1 Immunoassay 
Plate. Cover immunoassay plate. 
4. Incubate plate at room temperature for 30 minutes. 
5. Wash wells 6X with 1X Wash Buffer. 
6. Add 100µL diluted Anti-Human HO-1 to each well. Cover immunoassay plate. 
7. Incubate plate at room temperature for 1 hour. 
8. Wash wells 6X with 1X Wash Buffer. 
9. Add 100µL diluted Anti-Rabbit IgG:HRP Conjugate to each well. Cover immunoassay plate. 
10. Incubate plate at room temperature for 30 minutes. 
11. Wash wells 6X with 1X Wash Buffer. 
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12. Add 100µL TMB Substrate to each well. 
13. Incubate at room temperature for 15 minutes (preferably in the dark). 
14. Add 100µL Acid Stop Solution to each well. 
15. Measure absorbance at 450nm. 
16. Plot the HO-1 standard curve and calculate HO-1 sample concentrations. 
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